ClinicalTrials.gg
CompletedNCT01774786JACOBUpdated Dec 30, 2020Results posted

A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer

A Phase 3 interventional study of 5-Fluorouracil and Capecitabine in Gastric Cancer, sponsored by Hoffmann-La Roche. Completed at 172 sites in 32 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-30.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
780
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Stomach Neoplasms by Hoffmann-La Roche — none open to participants now, 2 under way, none of them phase 3. Stomach Neoplasms · Hoffmann-La Roche.

Enrollment
2nd of 23
780 · median 158
Started
2013
with 3 others
Phase 3
7 of 29
none open now
Registered
16th of 29
by date

Among the 29 studies in Stomach Neoplasms by Hoffmann-La Roche, this one is the 2nd largest by enrollment of the 23 interventional ones that give a count, is one of 4 that started in 2013, is one of 7 in phase 3, and was the 16th registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

None of the 29 studies in Stomach Neoplasms by Hoffmann-La Roche is open now. The open studies under Stomach Neoplasms, anywhere →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 29 studies in Stomach Neoplasms by Hoffmann-La Roche as a file.
02

Study summary

This double-blind, placebo-controlled, randomized, multicenter, international, parallel arm study will evaluate the efficacy and safety of pertuzumab in combination with trastuzumab, fluoropyrimidine and cisplatin as first-line treatment in participants with HER2-positive metastatic gastroesophageal junction (GEJ) or gastric cancer (GC). Participants will be randomized to receive pertuzumab 840 milligrams (mg) or placebo intravenously every 3 weeks (q3w) in combination with trastuzumab (initial dose of 8 milligrams per kilogram [mg/kg] intravenously [IV] followed by 6 mg/kg IV q3w) and cisplatin and fluoropyrimidine (capecitabine or 5-fluorouracil) for the first 6 treatment cycles. Participants will continue to receive pertuzumab or placebo and trastuzumab until disease progression occurrence of unacceptable toxicity or withdrawal from the study for another reason.

03

Conditions studied

  • Gastric Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed adenocarcinoma of the stomach or GEJ
  • Measurable or evaluable non- as assessed by the investigator according to v1.1 criteria
  • (ECOG) performance status 0 or 1
  • greater than equal to (>/=) 3 months

Exclusion criteria

Exclusion Criteria:

  • Previous cytotoxic chemotherapy for advanced () disease
  • Evidence of disease progression documented within 6 months after completion of prior or adjuvant cytotoxic chemotherapy, or both, or radiotherapy for GEJ adenocarcinoma
  • Previous treatment with any -directed therapy, at any time, for any duration
  • Previous exposure to any treatment within 30 days before the first dose of study treatment
  • Radiotherapy within 30 days before the first dose of study treatment (within 2 weeks if given as palliation to bone metastases, if recovered from all toxicities)
  • History or evidence of
  • active gastrointestinal (GI) bleeding (Grade >/=2 according to National Cancer Institute [NIC]- Version 4.0 [CTCAEv.4.0])
  • Residual toxicity resulting from previous therapy (for example, hematologic, cardiovascular, or neurologic toxicity that is Grade >/=2). Alopecia is permitted
  • Other (in addition to gastric cancer [GC]) within 5 years before enrollment, except for carcinoma in situ of the cervix or squamous or basal cell carcinoma of the skin that has been previously treated with curative intent
  • Inadequate hematologic, renal or liver function
  • Pregnant or lactating women
  • History of congestive heart failure of any (NYHA) criteria
  • Angina pectoris requiring treatment
  • Myocardial infarction within the past 6 months before the first dose of study drug
  • Clinically significant valvular heart disease or uncontrollable high-risk cardiac arrhythmia
  • History or evidence of poorly controlled hypertension
  • Baseline (LVEF) value less than (\<) 55 percent (%)
  • Any significant uncontrolled intercurrent systemic illness
  • Positive for , or (HIV) infection
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
780 participants (actual)

Study arms

  • Experimental
    Pertuzumab + Trastuzumab + Chemotherapy

    Participants will receive pertuzumab in combination with trastuzumab and chemotherapy (cisplatin and fluoropyrimidine \[capecitabine or 5-fluorouracil\]) for the first 6 treatment cycles (cycle length = 21 days). Thereafter, participants will continue to receive pertuzumab and trastuzumab until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.

    Drug: 5-Fluorouracil · Drug: Capecitabine · Drug: Cisplatin · Drug: Pertuzumab · Drug: Trastuzumab

  • Placebo comparator
    Placebo + Trastuzumab + Chemotherapy

    Participants will receive placebo in combination with trastuzumab and chemotherapy (cisplatin and fluoropyrimidine \[capecitabine or 5-fluorouracil\]) for the first 6 treatment cycles (cycle length = 21 days). Thereafter, participants will continue to receive placebo and trastuzumab until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.

    Drug: 5-Fluorouracil · Drug: Capecitabine · Drug: Cisplatin · Drug: Placebo · Drug: Trastuzumab

Interventions

  • Participants will receive 5-fluorouracil 800 milligrams per meter square (mg/m\^2)/24 hour IV infusion for 120 hours (Days 1-5) q3w for 6 cycles.

  • Participants will receive capecitabine 1000 mg/m\^2 orally twice daily, evening of Day 1 to morning of Day 15 (28 doses) q3w for 6 cycles.

    Also known as: Xeloda

  • Participants will receive cisplatin 80 mg/m\^2 IV q3w for 6 cycles.

  • Participants will receive pertuzumab 840 mg IV q3w until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.

    Also known as: Perjeta, RO4368451

  • DrugPlacebo

    Participants will receive placebo (matched to pertuzumab) IV q3w until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.

  • Participants will receive 8 mg/kg IV initial dose on Day 1, followed by 6 mg/kg IV q3w until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.

    Also known as: Herceptin, RO0452317

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Overall survival (OS) was defined as the time from randomization to death from any cause. For participants who were still alive on the date of clinical data cut-off for the OS analysis, the last date when the participant was known to be alive on, or prior to the clinical cut-off date, was used to determine the censoring date. Participants who did not have any post-baseline data (e.g., dosing records, imaging dates, visit dates) were censored at the date of randomization plus 1 day.

    Time frame: From Baseline until death from any cause (Median [full range] duration of follow-up in Pertuzumab vs. Placebo arms for Primary Analysis: 24.4 [0-42] months vs. 25.0 [0-41] months; Final Analysis: 46.1 [0-70] months vs. 44.4 [0-68] months)

Secondary outcomes

  1. Progression-Free Survival, as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Criteria

    Progression-free survival (PFS) is defined as the time from randomization to the first occurrence of progressive disease (PD), as determined by the investigator using RECIST v1.1, or death from any cause, whichever occurred first. Tumor assessments with CT or MRI scans of the chest, abdomen, and pelvis were performed every 9 weeks. Participants without documented PD or death were censored at the tumor assessment date for which the participant was last known to be progression-free. Participants who did not have any post-baseline tumor assessment data were censored at the date of randomization plus 1 day. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline; an absolute increase of at least 5 millimeters (mm) in the sum of diameters of target lesions; the appearance of one or more new lesions.

    Time frame: Baseline to death or progressive disease (PD), whichever occurred first (Median [full range] duration of follow-up in Pertuzumab vs. Placebo arms for Primary Analysis: 24.9 [0-41] vs. 21.3 [0-39] months; Final Analysis: 50.4 [0-70] vs. 47.4 [0-66] months)

  2. Primary Analysis of the Percentage of Participants With Overall Objective Response, as Determined by the Investigator According to RECIST v1.1 Criteria

    The overall objective response rate was defined as the percentage of participants with partial response (PR) or complete response (CR) occurring on two consecutive occasions ≥4 weeks apart, as determined by the investigator using RECIST v1.1. Tumor assessments with computed tomography (CT) or magnetic resonance imaging (MRI) scans of the chest, abdomen, and pelvis were performed every 9 weeks. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR: disappearance of all target lesions. Measurable disease is defined as tumor lesions measured in at least one dimension (longest diameter in plane of measurement) with a minimum size of: 10 mm by CT or MRI scan; 10 mm caliper measurement by clinical examination; 20 mm by chest X-ray. For a malignant lymph node to be considered pathologically enlarged and measurable, it must be greater than or equal to (≥) 15 mm in short axis when assessed by CT scan.

    Time frame: Baseline up to death or progressive disease, whichever occurred first (Median [full range] duration of follow-up in Pertuzumab vs. Placebo arms for Primary Analysis: 24.9 [0-41] months vs. 21.3 [0-39] months)

  3. Final Analysis of the Percentage of Participants With Overall Objective Response, as Determined by the Investigator According to RECIST v1.1 Criteria

    The overall objective response rate was defined as the percentage of participants with partial response (PR) or complete response (CR) occurring on two consecutive occasions ≥4 weeks apart, as determined by the investigator using RECIST v1.1. Tumor assessments with computed tomography (CT) or magnetic resonance imaging (MRI) scans of the chest, abdomen, and pelvis were performed every 9 weeks. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR: disappearance of all target lesions. Measurable disease is defined as tumor lesions measured in at least one dimension (longest diameter in plane of measurement) with a minimum size of: 10 mm by CT or MRI scan; 10 mm caliper measurement by clinical examination; 20 mm by chest X-ray. For a malignant lymph node to be considered pathologically enlarged and measurable, it must be greater than or equal to (≥) 15 mm in short axis when assessed by CT scan.

    Time frame: Baseline up to death or progressive disease, whichever occurred first (Median [full range] duration of follow-up in Pertuzumab vs. Placebo arms for Final Analysis: 50.4 [0-70] months vs. 47.4 [0-66] months)

  4. Duration of Objective Response, as Determined by Investigator According to RECIST v1.1 Criteria

    Duration of objective response is defined as the time from first occurrence of documented objective response to documented disease progression, as determined by the investigator using RECIST v1.1, or death from any cause. Objective response: PR or CR occurring on 2 consecutive occasions ≥4 weeks apart. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR: disappearance of all target lesions. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline; an absolute increase of at least 5 mm in the sum of diameters of target lesions; the appearance of one or more new lesions. Measurable disease defined as tumor lesions with a minimum size of: 10 mm by CT or MRI scan; 10 mm caliper measurement by clinical examination; 20 mm by chest X-ray. For a malignant lymph node, it must be ≥15 mm in short axis when assessed by CT scan.

    Time frame: Baseline to death or progressive disease (PD), whichever occurred first (Median [full range] duration of follow-up in Pertuzumab vs. Placebo arms for Primary Analysis: 24.9 [0-41] vs. 21.3 [0-39] months; Final Analysis: 50.4 [0-70] vs. 47.4 [0-66] months)

  5. Percentage of Participants With Clinical Benefit, as Determined by the Investigator According to RECIST v1.1 Criteria

    The clinical benefit rate was defined as best response of complete response (CR) or partial response (PR) or stable disease (SD) for 6 weeks or longer, as determined by the investigator using RECIST v1.1. CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression, taking as reference the smallest sum diameters while on study. Measurable disease is defined as tumor lesions measured in at least one dimension (longest diameter in plane of measurement) with a minimum size of: 10 mm by CT or MRI scan; 10 mm caliper measurement by clinical examination; 20 mm by chest X-ray. For a malignant lymph node to be considered pathologically enlarged and measurable, it must be \>/=15 mm in short axis when assessed by CT scan. The clinical benefit rate was not updated at the final analysis.

    Time frame: Baseline up to death or progressive disease, whichever occurred first (Median [full range] duration of follow-up in Pertuzumab vs. Placebo arms for Primary Analysis: 24.9 [0-41] months vs. 21.3 [0-39] months)

  6. Overview of Safety: Number of Participants With at Least One Adverse Event, Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.03

    An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. The investigator graded all AEs for severity per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.03; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE.

    Time frame: From Baseline until end of post-treatment follow-up (up to 70 months)

  7. Number of Participants With Symptomatic or Asymptomatic Left Ventricular Systolic Dysfunction (LVSD)

    The number and percentage of participants with symptomatic left ventricular systolic dysfunction (LVSD) and asymptomatic LVSD events (defined as a left ventricular ejection fraction \[LVEF\] ≥10% decrease from baseline to an absolute value \<50%) at any time during the study was summarized by treatment arm.

    Time frame: From Baseline until end of post-treatment follow-up (up to 70 months)

  8. Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score

    The EORTC QLQ-C30 included global health status, functional scales (physical, role, emotional, cognitive, and social), symptom scales (fatigue, nausea/vomiting, and pain) and single items (dyspnoea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Most questions used a 4-point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale \[1 'very poor' to 7 'Excellent'\]). Scores were averaged and transformed to 0 - 100 scale, whereby higher scores indicate greater functioning, greater quality of life, or a greater degree of symptoms, with changes of 5 - 10 points considered to be a minimally important difference to participants. A positive value means an increase, while a negative value means a decrease, in score at the indicated time-point relative to the score at baseline (Cycle 1, Day 1).

    Time frame: Day 1 of each 21-day treatment cycle up to 28 and 60-90 days (post-treatment [PT] monitoring visits 1 and 2, respectively) after Day 1 of last treatment cycle (up to approximately 3.5 years)

  9. Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score

    The EORTC QLQ-STO22 is a gastric cancer quality of life questionnaire. There are 22 questions concerning disease, treatment related symptoms, side effects, dysphagia, nutritional aspects, and questions about the emotional problems of gastric cancer (dysphagia, pain, reflux, eating restrictions, anxiety, dry mouth, body image, and hair loss). The questions are grouped into five scales and 4 single items which are related to the symptoms of the disease. Most questions used 4-point scale (1 'Not at all' to 4 'Very much'; 1 question was a yes or no answer). A linear transformation was used to standardize all scores and single-items to a scale of 0 to 100; higher score=better level of functioning or greater degree of symptoms. A positive value means an increase, while a negative values means a decrease, in score at the indicated time-point relative to the score at baseline (Cycle 1, Day 1).

    Time frame: Day 1 of each 21-day treatment cycle up to 28 and 60-90 days (post-treatment [PT] monitoring visits 1 and 2, respectively) after Day 1 of last treatment cycle (up to approximately 3.5 years)

  10. Maximum Serum Concentration (Cmax) of Pertuzumab

    Time frame: Post-dose (0.5 hour after end of 30-60 minutes infusion) on Day 1 of Cycles 1, 2, 4, and 8 (1 cycle = 21 days)

  11. Cmax of Trastuzumab

    Time frame: Post-dose (0.5 hour after end of 30-60 minutes infusion) on Day 1 of Cycles 1, 2, 4, and 8 (1 cycle = 21 days)

  12. Minimum Serum Concentration (Cmin) of Pertuzumab

    Time frame: Pre-dose (0-6 hours before infusion) on Day 1 of Cycles 1, 2, 3, 4, 6, and 8 (1 cycle = 21 days)

  13. Cmin of Trastuzumab

    Time frame: Pre-dose (0-6 hours before infusion) on Day 1 of Cycles 1, 2, 3, 4, 6, and 8 (1 cycle = 21 days)

07

Results

Posted Feb 14, 2018

Participant flow

Participant flow — Overall Study
MilestonePertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
Started388392
Did not receive any study treatment43
Received at least one dose of pertuzumab3841
Received placebo (no pertuzumab)0388
Completed6046
Not completed328346
Withdrew: Death300319
Withdrew: Lost to follow-up67
Withdrew: Withdrawal by subject1814
Withdrew: Physician decision20
Withdrew: Non-compliance01
Withdrew: Reason not specified25

Outcome measures

PrimaryOverall Survival

Overall survival (OS) was defined as the time from randomization to death from any cause. For participants who were still alive on the date of clinical data cut-off for the OS analysis, the last date when the participant was known to be alive on, or prior to the clinical cut-off date, was used to determine the censoring date. Participants who did not have any post-baseline data (e.g., dosing records, imaging dates, visit dates) were censored at the date of randomization plus 1 day.

Time frame:
From Baseline until death from any cause (Median [full range] duration of follow-up in Pertuzumab vs. Placebo arms for Primary Analysis: 24.4 [0-42] months vs. 25.0 [0-41] months; Final Analysis: 46.1 [0-70] months vs. 44.4 [0-68] months)
Reported as:
Median · Months
Overall Survival
MonthsPertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
Primary Analysis17.5 (16.2 to 19.3)14.2 (12.9 to 15.5)
Final Analysis18.1 (16.2 to 19.5)14.2 (12.9 to 15.7)
Statistical analysis
  • Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy · Stratified Log-Rank · p = 0.0565 (The actual p-value significance threshold required for OS was 0.0455, after alpha spent at the interim analysis was taken into account.) · Hazard ratio (hr): 0.84 · 95% CI 0.71 to 1.00HR was calculated as pertuzumab arm vs. placebo arm.
  • Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy · Hazard ratio (hr): 0.85 · 95% CI 0.72 to 0.99HR was calculated as pertuzumab arm vs. placebo arm. Stratified analysis by geographic region, HER2 status, and prior gastrectomy.
SecondaryProgression-Free Survival, as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Criteria

Progression-free survival (PFS) is defined as the time from randomization to the first occurrence of progressive disease (PD), as determined by the investigator using RECIST v1.1, or death from any cause, whichever occurred first. Tumor assessments with CT or MRI scans of the chest, abdomen, and pelvis were performed every 9 weeks. Participants without documented PD or death were censored at the tumor assessment date for which the participant was last known to be progression-free. Participants who did not have any post-baseline tumor assessment data were censored at the date of randomization plus 1 day. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline; an absolute increase of at least 5 millimeters (mm) in the sum of diameters of target lesions; the appearance of one or more new lesions.

Time frame:
Baseline to death or progressive disease (PD), whichever occurred first (Median [full range] duration of follow-up in Pertuzumab vs. Placebo arms for Primary Analysis: 24.9 [0-41] vs. 21.3 [0-39] months; Final Analysis: 50.4 [0-70] vs. 47.4 [0-66] months)
Reported as:
Median · months
Progression-Free Survival, as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Criteria
monthsPertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
Primary Analysis8.5 (8.2 to 9.7)7.0 (6.4 to 8.2)
Final Analysis8.5 (8.3 to 9.7)7.2 (6.4 to 8.2)
Statistical analysis
  • Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy · Hazard ratio (hr): 0.73 · 95% CI 0.62 to 0.86A stratified Cox proportional hazards regression model was used to estimate the HR between the pertuzumab arm vs. the placebo arm.
  • Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy · Hazard ratio (hr): 0.73 · 95% CI 0.62 to 0.85A stratified Cox proportional hazards regression model was used to estimate the HR between the pertuzumab arm vs. the placebo arm.
SecondaryPrimary Analysis of the Percentage of Participants With Overall Objective Response, as Determined by the Investigator According to RECIST v1.1 Criteria

The overall objective response rate was defined as the percentage of participants with partial response (PR) or complete response (CR) occurring on two consecutive occasions ≥4 weeks apart, as determined by the investigator using RECIST v1.1. Tumor assessments with computed tomography (CT) or magnetic resonance imaging (MRI) scans of the chest, abdomen, and pelvis were performed every 9 weeks. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR: disappearance of all target lesions. Measurable disease is defined as tumor lesions measured in at least one dimension (longest diameter in plane of measurement) with a minimum size of: 10 mm by CT or MRI scan; 10 mm caliper measurement by clinical examination; 20 mm by chest X-ray. For a malignant lymph node to be considered pathologically enlarged and measurable, it must be greater than or equal to (≥) 15 mm in short axis when assessed by CT scan.

Time frame:
Baseline up to death or progressive disease, whichever occurred first (Median [full range] duration of follow-up in Pertuzumab vs. Placebo arms for Primary Analysis: 24.9 [0-41] months vs. 21.3 [0-39] months)
Reported as:
Number · Percentage of participants
Primary Analysis of the Percentage of Participants With Overall Objective Response, as Determined by the Investigator According to RECIST v1.1 Criteria
Percentage of participantsPertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
Objective Response (CR + PR)56.7 (51.33 to 61.95)48.3 (42.97 to 53.65)
Complete Response (CR)5.1 (3.07 to 7.98)0.9 (0.18 to 2.47)
Partial Response (PR)51.6 (46.20 to 56.91)47.4 (42.13 to 52.80)
Stable Disease (SD)27.9 (23.29 to 32.93)33.0 (28.06 to 38.14)
Progressive Disease (PD)4.8 (2.85 to 7.64)8.0 (5.35 to 11.29)
Not Evaluable/Missing10.5 (7.53 to 14.24)10.8 (7.75 to 14.52)
Statistical analysis
  • Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy · Difference in objective response: 8.40 · 95% CI 0.89 to 15.91Difference in objective response was calculated as the pertuzumab arm minus placebo arm.
  • Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy · Odds ratio (or): 1.40 · 95% CI 1.04 to 1.89Odds ratio was calculated as the pertuzumab arm vs. placebo arm.
SecondaryFinal Analysis of the Percentage of Participants With Overall Objective Response, as Determined by the Investigator According to RECIST v1.1 Criteria

The overall objective response rate was defined as the percentage of participants with partial response (PR) or complete response (CR) occurring on two consecutive occasions ≥4 weeks apart, as determined by the investigator using RECIST v1.1. Tumor assessments with computed tomography (CT) or magnetic resonance imaging (MRI) scans of the chest, abdomen, and pelvis were performed every 9 weeks. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR: disappearance of all target lesions. Measurable disease is defined as tumor lesions measured in at least one dimension (longest diameter in plane of measurement) with a minimum size of: 10 mm by CT or MRI scan; 10 mm caliper measurement by clinical examination; 20 mm by chest X-ray. For a malignant lymph node to be considered pathologically enlarged and measurable, it must be greater than or equal to (≥) 15 mm in short axis when assessed by CT scan.

Time frame:
Baseline up to death or progressive disease, whichever occurred first (Median [full range] duration of follow-up in Pertuzumab vs. Placebo arms for Final Analysis: 50.4 [0-70] months vs. 47.4 [0-66] months)
Reported as:
Number · Percentage of participants
Final Analysis of the Percentage of Participants With Overall Objective Response, as Determined by the Investigator According to RECIST v1.1 Criteria
Percentage of participantsPertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
Objective Response (CR + PR)57.0 (51.62 to 62.22)48.6 (43.25 to 53.94)
Complete Response (CR)5.7 (3.51 to 8.66)2.0 (0.80 to 4.05)
Partial Response (PR)51.3 (45.92 to 56.62)46.6 (41.29 to 51.95)
Stable Disease (SD)27.6 (23.02 to 32.63)32.7 (27.79 to 37.84)
Progressive Disease (PD)4.8 (2.85 to 7.64)8.2 (5.59 to 11.62)
Not Evaluable/Missing10.5 (7.53 to 14.24)10.5 (7.51 to 14.20)
Statistical analysis
  • Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy · Difference in objective response: 8.40 · 95% CI 0.89 to 15.91Difference in objective response was calculated as the pertuzumab arm minus placebo arm.
  • Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy · Odds ratio (or): 1.40 · 95% CI 1.04 to 1.89Odds ratio was calculated as the pertuzumab arm vs. placebo arm.
SecondaryDuration of Objective Response, as Determined by Investigator According to RECIST v1.1 Criteria

Duration of objective response is defined as the time from first occurrence of documented objective response to documented disease progression, as determined by the investigator using RECIST v1.1, or death from any cause. Objective response: PR or CR occurring on 2 consecutive occasions ≥4 weeks apart. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR: disappearance of all target lesions. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, including baseline; an absolute increase of at least 5 mm in the sum of diameters of target lesions; the appearance of one or more new lesions. Measurable disease defined as tumor lesions with a minimum size of: 10 mm by CT or MRI scan; 10 mm caliper measurement by clinical examination; 20 mm by chest X-ray. For a malignant lymph node, it must be ≥15 mm in short axis when assessed by CT scan.

Time frame:
Baseline to death or progressive disease (PD), whichever occurred first (Median [full range] duration of follow-up in Pertuzumab vs. Placebo arms for Primary Analysis: 24.9 [0-41] vs. 21.3 [0-39] months; Final Analysis: 50.4 [0-70] vs. 47.4 [0-66] months)
Reported as:
Median · months
Duration of Objective Response, as Determined by Investigator According to RECIST v1.1 Criteria
monthsPertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
Primary Analysis10.2 (8.4 to 10.7)8.4 (6.8 to 8.7)
Final Analysis10.2 (8.5 to 11.6)8.4 (6.7 to 9.0)
Statistical analysis
  • Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy · Hazard ratio (hr): 0.82 · 95% CI 0.64 to 1.06HR was calculated as pertuzumab arm vs. placebo arm. Stratified analysis by geographic region, HER2 status, and prior gastrectomy.
  • Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy · Hazard ratio (hr): 0.78 · 95% CI 0.62 to 0.98HR was calculated as pertuzumab arm vs. placebo arm. Stratified analysis by geographic region, HER2 status, and prior gastrectomy.
SecondaryPercentage of Participants With Clinical Benefit, as Determined by the Investigator According to RECIST v1.1 Criteria

The clinical benefit rate was defined as best response of complete response (CR) or partial response (PR) or stable disease (SD) for 6 weeks or longer, as determined by the investigator using RECIST v1.1. CR: disappearance of all target lesions. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression, taking as reference the smallest sum diameters while on study. Measurable disease is defined as tumor lesions measured in at least one dimension (longest diameter in plane of measurement) with a minimum size of: 10 mm by CT or MRI scan; 10 mm caliper measurement by clinical examination; 20 mm by chest X-ray. For a malignant lymph node to be considered pathologically enlarged and measurable, it must be \>/=15 mm in short axis when assessed by CT scan. The clinical benefit rate was not updated at the final analysis.

Time frame:
Baseline up to death or progressive disease, whichever occurred first (Median [full range] duration of follow-up in Pertuzumab vs. Placebo arms for Primary Analysis: 24.9 [0-41] months vs. 21.3 [0-39] months)
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Benefit, as Determined by the Investigator According to RECIST v1.1 Criteria
percentage of participantsPertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
Percentage of Participants With Clinical Benefit, as Determined by the Investigator According to RECIST v1.1 Criteria84.6 (80.41 to 88.23)81.3 (76.77 to 85.19)
Statistical analysis
  • Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy · Difference in clinical benefit rate: 3.37 · 95% CI -2.34 to 9.07Difference in clinical benefit rate was calculated as the pertuzumab arm minus placebo arm.
  • Pertuzumab + Trastuzumab + Chemotherapy vs Placebo + Trastuzumab + Chemotherapy · Odds ratio (or): 1.27 · 95% CI 0.86 to 1.88Odds ratio was calculated as the pertuzumab arm vs. placebo arm.
SecondaryOverview of Safety: Number of Participants With at Least One Adverse Event, Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.03

An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. The investigator graded all AEs for severity per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.03; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE.

Time frame:
From Baseline until end of post-treatment follow-up (up to 70 months)
Reported as:
Count of participants · Participants
Overview of Safety: Number of Participants With at Least One Adverse Event, Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.03
ParticipantsPertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
Any Adverse Event (AE)381385
AE with Fatal Outcome2731
Serious AE178156
Grade 3-5 AE310288
AE Leading to Pertuz/Pbo & Trastuz Discontinuation4846
AE Leading to Dose Interruption &/or Dose Delay11094
SecondaryNumber of Participants With Symptomatic or Asymptomatic Left Ventricular Systolic Dysfunction (LVSD)

The number and percentage of participants with symptomatic left ventricular systolic dysfunction (LVSD) and asymptomatic LVSD events (defined as a left ventricular ejection fraction \[LVEF\] ≥10% decrease from baseline to an absolute value \<50%) at any time during the study was summarized by treatment arm.

Time frame:
From Baseline until end of post-treatment follow-up (up to 70 months)
Reported as:
Count of participants · Participants
Number of Participants With Symptomatic or Asymptomatic Left Ventricular Systolic Dysfunction (LVSD)
ParticipantsPertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
Symptomatic LVSD31
Asymptomatic LVSD2018
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score

The EORTC QLQ-C30 included global health status, functional scales (physical, role, emotional, cognitive, and social), symptom scales (fatigue, nausea/vomiting, and pain) and single items (dyspnoea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Most questions used a 4-point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale \[1 'very poor' to 7 'Excellent'\]). Scores were averaged and transformed to 0 - 100 scale, whereby higher scores indicate greater functioning, greater quality of life, or a greater degree of symptoms, with changes of 5 - 10 points considered to be a minimally important difference to participants. A positive value means an increase, while a negative value means a decrease, in score at the indicated time-point relative to the score at baseline (Cycle 1, Day 1).

Time frame:
Day 1 of each 21-day treatment cycle up to 28 and 60-90 days (post-treatment [PT] monitoring visits 1 and 2, respectively) after Day 1 of last treatment cycle (up to approximately 3.5 years)
Reported as:
Mean · score on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Score
score on a scalePertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
Appetite Loss: Cycle 1 (Baseline)26.68 ± 28.6527.59 ± 29.96
Appetite Loss: Change at Cycle 26.57 ± 33.180.97 ± 35.86
Appetite Loss: Change at Cycle 33.63 ± 36.193.81 ± 36.76
Appetite Loss: Change at Cycle 45.24 ± 34.200.79 ± 34.33
Appetite Loss: Change at Cycle 54.55 ± 36.502.90 ± 35.85
Appetite Loss: Change at Cycle 63.94 ± 36.07-0.39 ± 36.86
Appetite Loss: Change at Cycle 72.07 ± 38.051.61 ± 35.98
Appetite Loss: Change at Cycle 8-2.42 ± 33.81-3.69 ± 34.20
Appetite Loss: Change at Cycle 9-6.67 ± 31.92-4.76 ± 31.67
Appetite Loss: Change at Cycle 10-8.06 ± 32.52-6.63 ± 28.48
Appetite Loss: Change at Cycle 11-9.36 ± 33.19-9.68 ± 27.38
Appetite Loss: Change at Cycle 12-9.22 ± 33.73-9.05 ± 28.51
Appetite Loss: Change at Cycle 13-10.17 ± 31.10-10.81 ± 29.18
Appetite Loss: Change at Cycle 14-12.10 ± 31.96-12.09 ± 30.32
Appetite Loss: Change at Cycle 15-8.21 ± 32.96-9.18 ± 29.81
Appetite Loss: Change at Cycle 16-6.03 ± 33.07-10.59 ± 28.74
Appetite Loss: Change at Cycle 17-6.55 ± 29.29-9.91 ± 29.05
Appetite Loss: Change at Cycle 18-4.90 ± 31.25-14.08 ± 27.98
Appetite Loss: Change at Cycle 19-8.33 ± 31.34-13.13 ± 28.57
Appetite Loss: Change at Cycle 20-3.97 ± 31.65-13.23 ± 29.66
Appetite Loss: Change at Cycle 21-5.91 ± 31.01-14.20 ± 32.76
Appetite Loss: Change at Cycle 22-4.98 ± 34.45-16.31 ± 29.38
Appetite Loss: Change at Cycle 23-6.35 ± 36.84-11.36 ± 35.90
Appetite Loss: Change at Cycle 24-7.78 ± 33.82-13.33 ± 30.00
Appetite Loss: Change at Cycle 25-7.05 ± 35.14-12.04 ± 31.02
Appetite Loss: Change at Cycle 26-7.48 ± 34.87-12.50 ± 32.52
Appetite Loss: Change at Cycle 27-10.08 ± 33.76-9.20 ± 28.03
Appetite Loss: Change at Cycle 28-10.00 ± 32.20-11.54 ± 29.73
Appetite Loss: Change at PT Visit 17.30 ± 36.862.64 ± 33.14
Appetite Loss: Change at PT Visit 2-0.33 ± 33.834.55 ± 34.53
Cognitive Functional Scale: Cycle 1 (Baseline)87.95 ± 17.3288.22 ± 16.18
Cognitive Functional Scale: Change at Cycle 2-1.90 ± 17.82-1.81 ± 16.93
Cognitive Functional Scale: Change at Cycle 3-0.83 ± 17.11-3.17 ± 18.30
Cognitive Functional Scale: Change at Cycle 4-2.04 ± 17.78-2.99 ± 19.28
Cognitive Functional Scale: Change at Cycle 5-3.04 ± 19.09-4.59 ± 19.59
Cognitive Functional Scale: Change at Cycle 6-5.10 ± 19.23-3.84 ± 19.00
Cognitive Functional Scale: Change at Cycle 7-4.34 ± 19.52-4.31 ± 19.09
Cognitive Functional Scale: Change at Cycle 8-3.15 ± 17.90-3.30 ± 17.59
Cognitive Functional Scale: Change at Cycle 9-2.22 ± 18.53-4.59 ± 18.53
Cognitive Functional Scale: Change at Cycle 10-3.32 ± 19.44-3.11 ± 18.50
Cognitive Functional Scale: Change at Cycle 11-2.83 ± 18.44-3.44 ± 17.06
Cognitive Functional Scale: Change at Cycle 12-3.35 ± 20.00-2.52 ± 18.16
Cognitive Functional Scale: Change at Cycle 13-1.79 ± 19.04-3.60 ± 17.89
Cognitive Functional Scale: Change at Cycle 14-1.98 ± 19.00-2.29 ± 17.56
Cognitive Functional Scale: Change at Cycle 15-1.15 ± 18.47-2.38 ± 16.05
Cognitive Functional Scale: Change at Cycle 16-2.73 ± 17.16-2.55 ± 17.16
Cognitive Functional Scale: Change at Cycle 17-2.53 ± 17.21-1.13 ± 15.44
Cognitive Functional Scale: Change at Cycle 18-2.78 ± 18.180.47 ± 16.42
Cognitive Functional Scale: Change at Cycle 19-1.04 ± 18.070.00 ± 14.62
Cognitive Functional Scale: Change at Cycle 20-2.18 ± 19.670.79 ± 15.68
Cognitive Functional Scale: Change at Cycle 21-2.11 ± 20.560.62 ± 16.50
Cognitive Functional Scale: Change at Cycle 22-4.73 ± 18.98-0.71 ± 18.04
Cognitive Functional Scale: Change at Cycle 23-2.38 ± 19.601.14 ± 17.75
Cognitive Functional Scale: Change at Cycle 24-2.78 ± 19.691.25 ± 16.18
Cognitive Functional Scale: Change at Cycle 25-5.45 ± 16.41-0.93 ± 18.66
Cognitive Functional Scale: Change at Cycle 26-2.38 ± 16.32-1.56 ± 18.63
Cognitive Functional Scale: Change at Cycle 27-3.88 ± 18.84-1.15 ± 18.33
Cognitive Functional Scale: Change at Cycle 28-3.75 ± 15.780.00 ± 20.00
Cognitive Functional Scale: Change at PT Visit 1-9.13 ± 21.90-9.16 ± 20.02
Cognitive Functional Scale: Change at PT Visit 2-8.42 ± 20.22-11.21 ± 22.48
Constipation Symptom Scale: Cycle 1 (Baseline)20.43 ± 28.4518.41 ± 27.13
Constipation Symptom Scale: Change at Cycle 2-5.39 ± 27.050.29 ± 27.23
Constipation Symptom Scale: Change at Cycle 3-7.48 ± 28.98-2.11 ± 27.65
Constipation Symptom Scale: Change at Cycle 4-5.32 ± 29.21-3.73 ± 28.26
Constipation Symptom Scale: Change at Cycle 5-5.94 ± 29.15-1.28 ± 27.64
Constipation Symptom Scale: Change at Cycle 6-7.13 ± 29.65-2.33 ± 30.24
Constipation Symptom Scale: Change at Cycle 7-8.13 ± 30.11-4.09 ± 29.06
Constipation Symptom Scale: Change at Cycle 8-8.05 ± 30.90-4.45 ± 27.32
Constipation Symptom Scale: Change at Cycle 9-10.00 ± 27.10-5.61 ± 26.74
Constipation Symptom Scale: Change at Cycle 10-9.32 ± 29.56-7.43 ± 26.81
Constipation Symptom Scale: Change at Cycle 11-9.16 ± 29.60-6.88 ± 27.84
Constipation Symptom Scale: Change at Cycle 12-10.27 ± 29.04-7.25 ± 25.39
Constipation Symptom Scale: Change at Cycle 13-11.19 ± 29.55-5.76 ± 26.27
Constipation Symptom Scale: Change at Cycle 14-11.60 ± 27.11-6.21 ± 26.00
Constipation Symptom Scale: Change at Cycle 15-10.51 ± 26.59-7.14 ± 24.52
Constipation Symptom Scale: Change at Cycle 16-8.62 ± 24.91-7.45 ± 25.39
Constipation Symptom Scale: Change at Cycle 17-8.33 ± 24.30-5.86 ± 18.59
Constipation Symptom Scale: Change at Cycle 18-7.52 ± 22.93-6.57 ± 26.20
Constipation Symptom Scale: Change at Cycle 19-3.47 ± 25.81-3.03 ± 25.97
Constipation Symptom Scale: Change at Cycle 20-3.97 ± 26.08-4.76 ± 26.68
Constipation Symptom Scale: Change at Cycle 21-3.80 ± 29.23-9.26 ± 25.42
Constipation Symptom Scale: Change at Cycle 22-4.98 ± 28.58-8.51 ± 27.34
Constipation Symptom Scale: Change at Cycle 23-6.35 ± 28.62-8.33 ± 26.04
Constipation Symptom Scale: Change at Cycle 24-7.78 ± 27.01-10.00 ± 26.37
Constipation Symptom Scale: Change at Cycle 25-7.05 ± 29.77-9.26 ± 28.30
Constipation Symptom Scale: Change at Cycle 26-6.12 ± 30.94-6.25 ± 23.09
Constipation Symptom Scale: Change at Cycle 27-7.75 ± 28.95-10.34 ± 26.88
Constipation Symptom Scale: Change at Cycle 28-6.67 ± 26.37-6.41 ± 21.12
Constipation Symptom Scale: Change at PT Visit 1-6.78 ± 31.45-4.62 ± 26.19
Constipation Symptom Scale: Change at PT Visit 2-6.93 ± 28.41-0.91 ± 31.11
Diarrhea Symptom Scale: Cycle 1 (Baseline)8.87 ± 17.709.16 ± 18.87
Diarrhea Symptom Scale: Change at Cycle 215.12 ± 30.425.20 ± 23.79
Diarrhea Symptom Scale: Change at Cycle 314.64 ± 27.714.99 ± 26.10
Diarrhea Symptom Scale: Change at Cycle 414.13 ± 27.154.63 ± 24.07
Diarrhea Symptom Scale: Change at Cycle 513.17 ± 25.474.99 ± 23.70
Diarrhea Symptom Scale: Change at Cycle 614.81 ± 27.012.47 ± 23.76
Diarrhea Symptom Scale: Change at Cycle 712.26 ± 23.742.92 ± 23.44
Diarrhea Symptom Scale: Change at Cycle 88.91 ± 23.562.61 ± 23.53
Diarrhea Symptom Scale: Change at Cycle 96.83 ± 23.762.04 ± 21.25
Diarrhea Symptom Scale: Change at Cycle 106.63 ± 23.970.60 ± 20.91
Diarrhea Symptom Scale: Change at Cycle 115.26 ± 21.802.60 ± 20.36
Diarrhea Symptom Scale: Change at Cycle 123.98 ± 22.301.92 ± 19.97
Diarrhea Symptom Scale: Change at Cycle 134.29 ± 24.271.50 ± 19.27
Diarrhea Symptom Scale: Change at Cycle 143.95 ± 24.450.98 ± 20.15
Diarrhea Symptom Scale: Change at Cycle 153.33 ± 23.791.02 ± 19.42
Diarrhea Symptom Scale: Change at Cycle 165.46 ± 21.063.14 ± 15.10
Diarrhea Symptom Scale: Change at Cycle 172.68 ± 21.052.25 ± 14.94
Diarrhea Symptom Scale: Change at Cycle 183.59 ± 21.953.29 ± 17.95
Diarrhea Symptom Scale: Change at Cycle 193.82 ± 19.862.02 ± 16.41
Diarrhea Symptom Scale: Change at Cycle 205.95 ± 19.473.70 ± 17.05
Diarrhea Symptom Scale: Change at Cycle 213.80 ± 23.261.85 ± 16.40
Diarrhea Symptom Scale: Change at Cycle 226.97 ± 24.984.26 ± 17.88
Diarrhea Symptom Scale: Change at Cycle 236.88 ± 21.728.33 ± 20.49
Diarrhea Symptom Scale: Change at Cycle 247.22 ± 22.213.33 ± 16.54
Diarrhea Symptom Scale: Change at Cycle 258.97 ± 23.912.78 ± 14.64
Diarrhea Symptom Scale: Change at Cycle 265.44 ± 21.895.21 ± 20.93
Diarrhea Symptom Scale: Change at Cycle 273.88 ± 22.073.45 ± 16.29
Diarrhea Symptom Scale: Change at Cycle 287.50 ± 27.722.56 ± 16.12
Diarrhea Symptom Scale: Change at PT Visit 18.14 ± 26.001.98 ± 24.35
Diarrhea Symptom Scale: Change at PT Visit 27.26 ± 25.654.24 ± 29.65
Dyspnoea Symptom Scale: Cycle 1 (Baseline)12.07 ± 17.9912.65 ± 20.20
Dyspnoea Symptom Scale: Change at Cycle 2-0.50 ± 19.040.29 ± 19.72
Dyspnoea Symptom Scale: Change at Cycle 3-0.31 ± 20.18-0.32 ± 20.38
Dyspnoea Symptom Scale: Change at Cycle 41.23 ± 20.311.81 ± 21.08
Dyspnoea Symptom Scale: Change at Cycle 52.58 ± 20.621.39 ± 21.18
Dyspnoea Symptom Scale: Change at Cycle 63.20 ± 23.790.39 ± 20.55
Dyspnoea Symptom Scale: Change at Cycle 70.00 ± 21.940.59 ± 20.07
Dyspnoea Symptom Scale: Change at Cycle 8-0.14 ± 21.990.93 ± 20.56
Dyspnoea Symptom Scale: Change at Cycle 9-1.12 ± 20.510.17 ± 18.95
Dyspnoea Symptom Scale: Change at Cycle 10-0.54 ± 21.561.00 ± 16.99
Dyspnoea Symptom Scale: Change at Cycle 11-2.16 ± 19.58-1.29 ± 17.77
Dyspnoea Symptom Scale: Change at Cycle 12-2.53 ± 19.75-0.71 ± 18.95
Dyspnoea Symptom Scale: Change at Cycle 13-1.43 ± 20.34-1.20 ± 16.77
Dyspnoea Symptom Scale: Change at Cycle 14-1.98 ± 19.00-2.61 ± 17.98
Dyspnoea Symptom Scale: Change at Cycle 15-2.84 ± 21.262.72 ± 18.95
Dyspnoea Symptom Scale: Change at Cycle 16-1.45 ± 20.421.18 ± 18.86
Dyspnoea Symptom Scale: Change at Cycle 17-1.82 ± 20.610.90 ± 19.87
Dyspnoea Symptom Scale: Change at Cycle 18-0.98 ± 20.15-2.35 ± 18.10
Dyspnoea Symptom Scale: Change at Cycle 19-1.74 ± 20.730.51 ± 18.15
Dyspnoea Symptom Scale: Change at Cycle 20-1.19 ± 20.98-1.06 ± 16.90
Dyspnoea Symptom Scale: Change at Cycle 211.27 ± 22.29-0.62 ± 19.95
Dyspnoea Symptom Scale: Change at Cycle 22-1.99 ± 22.380.71 ± 14.73
Dyspnoea Symptom Scale: Change at Cycle 23-1.59 ± 21.941.52 ± 14.30
Dyspnoea Symptom Scale: Change at Cycle 241.11 ± 22.10-1.67 ± 12.96
Dyspnoea Symptom Scale: Change at Cycle 250.64 ± 21.38-3.70 ± 15.49
Dyspnoea Symptom Scale: Change at Cycle 260.00 ± 22.571.04 ± 23.16
Dyspnoea Symptom Scale: Change at Cycle 270.78 ± 21.193.45 ± 22.44
Dyspnoea Symptom Scale: Change at Cycle 281.67 ± 21.283.85 ± 17.20
Dyspnoea Symptom Scale: Change at PT Visit 16.97 ± 26.986.77 ± 23.82
Dyspnoea Symptom Scale: Change at PT Visit 23.30 ± 23.819.39 ± 26.76
Emotional Functional Scale: Cycle 1 (Baseline)76.90 ± 20.2176.56 ± 19.84
Emotional Functional Scale: Change at Cycle 23.53 ± 16.843.05 ± 18.49
Emotional Functional Scale: Change at Cycle 32.65 ± 18.633.96 ± 19.95
Emotional Functional Scale: Change at Cycle 43.10 ± 21.113.67 ± 20.44
Emotional Functional Scale: Change at Cycle 52.62 ± 19.972.74 ± 21.72
Emotional Functional Scale: Change at Cycle 61.01 ± 19.644.93 ± 21.00
Emotional Functional Scale: Change at Cycle 71.72 ± 21.094.41 ± 20.18
Emotional Functional Scale: Change at Cycle 83.43 ± 20.665.66 ± 19.63
Emotional Functional Scale: Change at Cycle 94.72 ± 20.104.78 ± 19.45
Emotional Functional Scale: Change at Cycle 103.72 ± 21.766.74 ± 18.13
Emotional Functional Scale: Change at Cycle 115.85 ± 19.644.96 ± 19.21
Emotional Functional Scale: Change at Cycle 124.93 ± 21.385.24 ± 19.14
Emotional Functional Scale: Change at Cycle 135.00 ± 23.075.18 ± 17.95
Emotional Functional Scale: Change at Cycle 145.93 ± 22.906.29 ± 19.03
Emotional Functional Scale: Change at Cycle 156.03 ± 22.135.19 ± 19.61
Emotional Functional Scale: Change at Cycle 165.17 ± 23.205.29 ± 20.81
Emotional Functional Scale: Change at Cycle 176.01 ± 23.556.31 ± 18.70
Emotional Functional Scale: Change at Cycle 183.68 ± 24.115.87 ± 19.39
Emotional Functional Scale: Change at Cycle 194.69 ± 26.015.56 ± 18.68
Emotional Functional Scale: Change at Cycle 203.47 ± 26.925.42 ± 17.91
Emotional Functional Scale: Change at Cycle 214.54 ± 26.556.48 ± 22.00
Emotional Functional Scale: Change at Cycle 225.35 ± 28.676.91 ± 18.66
Emotional Functional Scale: Change at Cycle 235.82 ± 28.426.63 ± 21.00
Emotional Functional Scale: Change at Cycle 245.28 ± 26.228.54 ± 19.57
Emotional Functional Scale: Change at Cycle 255.93 ± 25.488.80 ± 20.89
Emotional Functional Scale: Change at Cycle 265.44 ± 27.775.99 ± 16.15
Emotional Functional Scale: Change at Cycle 277.56 ± 28.345.75 ± 18.51
Emotional Functional Scale: Change at Cycle 287.08 ± 25.437.05 ± 18.96
Emotional Functional Scale: Change at PT Visit 1-5.48 ± 23.16-3.92 ± 23.28
Emotional Functional Scale: Change at PT Visit 2-2.64 ± 23.33-4.47 ± 23.34
Fatigue Symptom Scale: Cycle 1 (Baseline)31.96 ± 23.4632.27 ± 21.92
Fatigue Symptom Scale: Change at Cycle 23.13 ± 19.802.32 ± 21.57
Fatigue Symptom Scale: Change at Cycle 31.41 ± 22.653.19 ± 22.97
Fatigue Symptom Scale: Change at Cycle 42.77 ± 23.141.58 ± 24.04
Fatigue Symptom Scale: Change at Cycle 53.87 ± 25.753.05 ± 24.29
Fatigue Symptom Scale: Change at Cycle 64.37 ± 25.642.62 ± 23.68
Fatigue Symptom Scale: Change at Cycle 72.36 ± 26.790.97 ± 23.44
Fatigue Symptom Scale: Change at Cycle 8-0.19 ± 25.00-1.18 ± 22.74
Fatigue Symptom Scale: Change at Cycle 9-2.38 ± 22.69-2.01 ± 22.84
Fatigue Symptom Scale: Change at Cycle 10-3.41 ± 24.69-3.08 ± 22.41
Fatigue Symptom Scale: Change at Cycle 11-4.35 ± 22.66-3.44 ± 21.21
Fatigue Symptom Scale: Change at Cycle 12-3.14 ± 24.56-4.60 ± 24.39
Fatigue Symptom Scale: Change at Cycle 13-4.57 ± 23.31-4.50 ± 21.47
Fatigue Symptom Scale: Change at Cycle 14-6.75 ± 24.32-6.54 ± 22.89
Fatigue Symptom Scale: Change at Cycle 15-5.47 ± 24.68-4.99 ± 22.40
Fatigue Symptom Scale: Change at Cycle 16-3.54 ± 24.81-6.93 ± 21.89
Fatigue Symptom Scale: Change at Cycle 17-4.27 ± 25.50-3.45 ± 21.91
Fatigue Symptom Scale: Change at Cycle 18-4.14 ± 24.42-8.92 ± 20.54
Fatigue Symptom Scale: Change at Cycle 19-5.32 ± 27.83-9.01 ± 20.71
Fatigue Symptom Scale: Change at Cycle 20-5.56 ± 26.64-6.53 ± 21.83
Fatigue Symptom Scale: Change at Cycle 21-3.94 ± 25.97-7.41 ± 23.45
Fatigue Symptom Scale: Change at Cycle 22-1.49 ± 25.58-10.64 ± 22.22
Fatigue Symptom Scale: Change at Cycle 23-5.82 ± 25.23-9.60 ± 28.01
Fatigue Symptom Scale: Change at Cycle 24-1.67 ± 27.05-12.50 ± 24.29
Fatigue Symptom Scale: Change at Cycle 25-4.70 ± 26.16-12.35 ± 22.03
Fatigue Symptom Scale: Change at Cycle 26-4.99 ± 24.85-11.46 ± 22.84
Fatigue Symptom Scale: Change at Cycle 27-6.98 ± 23.76-5.36 ± 23.87
Fatigue Symptom Scale: Change at Cycle 28-6.39 ± 18.98-4.70 ± 26.14
Fatigue Symptom Scale: Change at PT Visit 110.02 ± 28.485.25 ± 24.00
Fatigue Symptom Scale: Change at PT Visit 27.70 ± 27.659.70 ± 25.01
Financial Difficulties Scale: Cycle 1 (Baseline)26.67 ± 30.3226.21 ± 29.78
Financial Difficulties Scale: Change at Cycle 2-0.90 ± 26.85-2.46 ± 25.46
Financial Difficulties Scale: Change at Cycle 30.31 ± 27.620.00 ± 26.33
Financial Difficulties Scale: Change at Cycle 40.89 ± 25.950.11 ± 25.10
Financial Difficulties Scale: Change at Cycle 51.75 ± 27.712.58 ± 26.46
Financial Difficulties Scale: Change at Cycle 61.11 ± 27.620.92 ± 26.36
Financial Difficulties Scale: Change at Cycle 71.11 ± 31.080.30 ± 26.41
Financial Difficulties Scale: Change at Cycle 81.15 ± 30.210.47 ± 25.27
Financial Difficulties Scale: Change at Cycle 91.11 ± 29.78-0.51 ± 24.75
Financial Difficulties Scale: Change at Cycle 100.90 ± 30.10-2.42 ± 24.30
Financial Difficulties Scale: Change at Cycle 110.39 ± 29.37-0.22 ± 24.84
Financial Difficulties Scale: Change at Cycle 12-1.05 ± 28.91-0.97 ± 26.39
Financial Difficulties Scale: Change at Cycle 13-0.95 ± 28.820.30 ± 24.82
Financial Difficulties Scale: Change at Cycle 14-1.73 ± 29.74-0.98 ± 25.02
Financial Difficulties Scale: Change at Cycle 15-1.81 ± 28.961.36 ± 26.18
Financial Difficulties Scale: Change at Cycle 16-3.16 ± 30.130.39 ± 25.97
Financial Difficulties Scale: Change at Cycle 17-3.87 ± 29.591.35 ± 27.28
Financial Difficulties Scale: Change at Cycle 18-2.29 ± 27.462.35 ± 26.02
Financial Difficulties Scale: Change at Cycle 19-0.35 ± 28.41-0.51 ± 27.73
Financial Difficulties Scale: Change at Cycle 201.19 ± 29.471.59 ± 27.71
Financial Difficulties Scale: Change at Cycle 211.27 ± 28.96-4.94 ± 27.78
Financial Difficulties Scale: Change at Cycle 222.49 ± 26.79-4.26 ± 23.69
Financial Difficulties Scale: Change at Cycle 23-0.53 ± 26.43-2.27 ± 29.11
Financial Difficulties Scale: Change at Cycle 241.11 ± 24.52-5.83 ± 26.03
Financial Difficulties Scale: Change at Cycle 253.21 ± 27.42-4.63 ± 25.39
Financial Difficulties Scale: Change at Cycle 262.72 ± 28.74-2.22 ± 26.16
Financial Difficulties Scale: Change at Cycle 27-3.10 ± 23.921.15 ± 24.37
Financial Difficulties Scale: Change at Cycle 28-1.67 ± 23.81-1.28 ± 24.00
Financial Difficulties Scale: Change at PT Visit 11.70 ± 29.661.33 ± 26.21
Financial Difficulties Scale: Change at PT Visit 21.98 ± 26.174.24 ± 31.32
Nausea and Vomiting Scale: Cycle 1 (Baseline)11.14 ± 19.1111.92 ± 18.76
Nausea And Vomiting Scale: Change at Cycle 25.85 ± 22.654.08 ± 22.25
Nausea And Vomiting Scale: Change at Cycle 35.12 ± 23.625.06 ± 21.14
Nausea And Vomiting Scale: Change at Cycle 44.10 ± 21.853.56 ± 23.76
Nausea And Vomiting Scale: Change at Cycle 55.13 ± 22.585.15 ± 23.81
Nausea And Vomiting Scale: Change at Cycle 64.11 ± 23.362.59 ± 21.24
Nausea And Vomiting Scale: Change at Cycle 72.07 ± 23.582.49 ± 22.31
Nausea And Vomiting Scale: Change at Cycle 8-0.86 ± 20.80-0.77 ± 20.21
Nausea And Vomiting Scale: Change at Cycle 9-2.54 ± 20.85-2.98 ± 19.78
Nausea And Vomiting Scale: Change at Cycle 10-4.30 ± 18.81-2.81 ± 20.57
Nausea And Vomiting Scale: Change at Cycle 11-3.51 ± 18.01-3.66 ± 20.04
Nausea And Vomiting Scale: Change at Cycle 12-3.04 ± 18.07-3.45 ± 20.34
Nausea And Vomiting Scale: Change at Cycle 13-4.02 ± 16.29-3.60 ± 19.25
Nausea And Vomiting Scale: Change at Cycle 14-3.46 ± 19.54-5.72 ± 18.54
Nausea And Vomiting Scale: Change at Cycle 15-3.59 ± 16.34-3.91 ± 16.55
Nausea And Vomiting Scale: Change at Cycle 16-0.43 ± 20.32-2.55 ± 20.00
Nausea And Vomiting Scale: Change at Cycle 17-0.60 ± 17.46-3.15 ± 16.48
Nausea And Vomiting Scale: Change at Cycle 18-0.65 ± 16.90-3.52 ± 18.24
Nausea And Vomiting Scale: Change at Cycle 19-0.87 ± 18.32-4.04 ± 19.62
Nausea And Vomiting Scale: Change at Cycle 20-1.79 ± 18.48-3.97 ± 17.89
Nausea And Vomiting Scale: Change at Cycle 21-1.05 ± 20.03-6.48 ± 19.80
Nausea And Vomiting Scale: Change at Cycle 22-3.48 ± 19.14-8.16 ± 18.99
Nausea And Vomiting Scale: Change at Cycle 23-4.23 ± 17.70-6.44 ± 24.70
Nausea And Vomiting Scale: Change at Cycle 24-4.72 ± 16.26-7.92 ± 17.70
Nausea And Vomiting Scale: Change at Cycle 25-4.17 ± 20.84-7.41 ± 19.29
Nausea And Vomiting Scale: Change at Cycle 26-3.40 ± 24.29-9.38 ± 19.37
Nausea And Vomiting Scale: Change at Cycle 27-5.04 ± 22.58-7.47 ± 20.70
Nausea And Vomiting Scale: Change at Cycle 28-1.25 ± 20.11-6.41 ± 17.69
Nausea and Vomiting Scale: Change at PT Visit 14.68 ± 22.204.13 ± 23.91
Nausea and Vomiting Scale: Change at PT Visit 24.29 ± 23.052.73 ± 21.60
Pain Symptom Scale: Cycle 1 (Baseline)23.92 ± 25.9223.72 ± 24.82
Pain Symptom Scale: Change at Cycle 2-6.80 ± 24.69-6.38 ± 23.58
Pain Symptom Scale: Change at Cycle 3-9.89 ± 25.16-7.23 ± 25.78
Pain Symptom Scale: Change at Cycle 4-10.26 ± 24.78-7.46 ± 26.06
Pain Symptom Scale: Change at Cycle 5-8.86 ± 25.88-6.25 ± 25.42
Pain Symptom Scale: Change at Cycle 6-8.95 ± 25.73-7.33 ± 24.85
Pain Symptom Scale: Change at Cycle 7-10.95 ± 26.13-7.46 ± 24.79
Pain Symptom Scale: Change at Cycle 8-9.97 ± 25.80-8.53 ± 22.86
Pain Symptom Scale: Change at Cycle 9-9.29 ± 24.83-7.82 ± 22.98
Pain Symptom Scale: Change at Cycle 10-9.41 ± 26.10-8.13 ± 22.75
Pain Symptom Scale: Change at Cycle 11-10.33 ± 25.77-6.34 ± 22.97
Pain Symptom Scale: Change at Cycle 12-10.27 ± 23.10-5.24 ± 25.29
Pain Symptom Scale: Change at Cycle 13-10.28 ± 25.79-4.80 ± 20.27
Pain Symptom Scale: Change at Cycle 14-10.49 ± 25.49-5.56 ± 23.37
Pain Symptom Scale: Change at Cycle 15-11.15 ± 22.86-3.74 ± 22.77
Pain Symptom Scale: Change at Cycle 16-9.91 ± 22.94-4.71 ± 23.66
Pain Symptom Scale: Change at Cycle 17-7.59 ± 25.00-5.63 ± 22.63
Pain Symptom Scale: Change at Cycle 18-8.82 ± 23.42-8.22 ± 20.68
Pain Symptom Scale: Change at Cycle 19-8.16 ± 25.13-5.05 ± 21.48
Pain Symptom Scale: Change at Cycle 20-6.94 ± 25.90-6.08 ± 19.24
Pain Symptom Scale: Change at Cycle 21-9.92 ± 27.15-6.48 ± 23.44
Pain Symptom Scale: Change at Cycle 22-7.71 ± 26.96-8.51 ± 19.62
Pain Symptom Scale: Change at Cycle 23-10.85 ± 22.03-7.95 ± 26.29
Pain Symptom Scale: Change at Cycle 24-10.00 ± 24.39-10.00 ± 17.21
Pain Symptom Scale: Change at Cycle 25-9.94 ± 24.09-12.96 ± 19.96
Pain Symptom Scale: Change at Cycle 26-10.54 ± 22.49-8.33 ± 18.45
Pain Symptom Scale: Change at Cycle 27-11.24 ± 22.34-5.75 ± 21.95
Pain Symptom Scale: Change at Cycle 28-10.42 ± 27.91-9.62 ± 19.54
Pain Symptom Scale: Change at PT Visit 11.13 ± 27.272.06 ± 28.70
Pain Symptom Scale: Change at PT Visit 2-1.49 ± 28.395.45 ± 29.96
Physical Functional Scale: Cycle 1 (Baseline)80.86 ± 19.5382.05 ± 18.32
Physical Functional Scale: Change at Cycle 2-3.58 ± 14.56-3.01 ± 15.34
Physical Functional Scale: Change at Cycle 3-2.99 ± 17.19-3.92 ± 17.03
Physical Functional Scale: Change at Cycle 4-3.28 ± 18.87-3.50 ± 17.99
Physical Functional Scale: Change at Cycle 5-3.10 ± 19.35-4.62 ± 17.62
Physical Functional Scale: Change at Cycle 6-5.00 ± 20.30-3.84 ± 18.65
Physical Functional Scale: Change at Cycle 7-3.66 ± 20.75-3.79 ± 19.82
Physical Functional Scale: Change at Cycle 8-2.24 ± 21.14-1.56 ± 18.55
Physical Functional Scale: Change at Cycle 9-1.59 ± 20.21-0.75 ± 18.44
Physical Functional Scale: Change at Cycle 100.11 ± 19.93-0.27 ± 17.16
Physical Functional Scale: Change at Cycle 110.35 ± 19.430.27 ± 17.09
Physical Functional Scale: Change at Cycle 12-1.05 ± 20.060.89 ± 16.35
Physical Functional Scale: Change at Cycle 13-0.80 ± 20.650.27 ± 17.41
Physical Functional Scale: Change at Cycle 14-0.02 ± 20.141.70 ± 18.09
Physical Functional Scale: Change at Cycle 150.41 ± 18.91-0.95 ± 17.99
Physical Functional Scale: Change at Cycle 16-1.08 ± 19.85-0.08 ± 18.18
Physical Functional Scale: Change at Cycle 17-0.46 ± 19.43-0.81 ± 17.55
Physical Functional Scale: Change at Cycle 180.13 ± 19.740.75 ± 16.85
Physical Functional Scale: Change at Cycle 191.39 ± 19.821.31 ± 14.38
Physical Functional Scale: Change at Cycle 200.71 ± 21.080.85 ± 16.74
Physical Functional Scale: Change at Cycle 210.42 ± 22.200.25 ± 18.18
Physical Functional Scale: Change at Cycle 22-2.79 ± 21.901.42 ± 16.79
Physical Functional Scale: Change at Cycle 23-1.48 ± 21.470.61 ± 19.60
Physical Functional Scale: Change at Cycle 24-2.67 ± 22.273.00 ± 16.47
Physical Functional Scale: Change at Cycle 25-2.18 ± 20.614.81 ± 15.91
Physical Functional Scale: Change at Cycle 26-1.90 ± 20.09-1.88 ± 20.69
Physical Functional Scale: Change at Cycle 270.16 ± 18.66-3.68 ± 19.40
Physical Functional Scale: Change at Cycle 28-1.17 ± 17.79-2.82 ± 18.97
Physical Functional Scale: Change at PT Visit 1-11.37 ± 23.67-7.51 ± 20.53
Physical Functional Scale: Change at PT Visit 2-11.49 ± 24.31-11.82 ± 20.27
Global Health Status Scale: Cycle 1 (Baseline)59.77 ± 22.8859.90 ± 22.11
Global Health Status Scale: Change at Cycle 21.81 ± 23.354.29 ± 23.42
Global Health Status Scale: Change at Cycle 31.56 ± 25.052.86 ± 25.03
Global Health Status Scale: Change at Cycle 41.39 ± 25.264.15 ± 23.79
Global Health Status Scale: Change at Cycle 51.17 ± 25.703.92 ± 23.05
Global Health Status Scale: Change at Cycle 60.68 ± 27.893.61 ± 23.13
Global Health Status Scale: Change at Cycle 71.83 ± 27.813.33 ± 22.77
Global Health Status Scale: Change at Cycle 83.06 ± 27.095.18 ± 23.18
Global Health Status Scale: Change at Cycle 94.39 ± 26.254.68 ± 22.99
Global Health Status Scale: Change at Cycle 104.80 ± 25.355.07 ± 22.77
Global Health Status Scale: Change at Cycle 115.78 ± 26.623.82 ± 23.75
Global Health Status Scale: Change at Cycle 123.11 ± 24.895.34 ± 24.47
Global Health Status Scale: Change at Cycle 133.51 ± 23.823.83 ± 23.78
Global Health Status Scale: Change at Cycle 145.97 ± 23.094.82 ± 24.86
Global Health Status Scale: Change at Cycle 154.26 ± 25.981.70 ± 24.46
Global Health Status Scale: Change at Cycle 163.12 ± 25.163.04 ± 23.77
Global Health Status Scale: Change at Cycle 172.93 ± 24.843.83 ± 24.84
Global Health Status Scale: Change at Cycle 183.02 ± 23.882.58 ± 27.08
Global Health Status Scale: Change at Cycle 193.25 ± 26.393.97 ± 25.43
Global Health Status Scale: Change at Cycle 205.12 ± 24.204.89 ± 25.69
Global Health Status Scale: Change at Cycle 215.38 ± 23.875.40 ± 24.72
Global Health Status Scale: Change at Cycle 223.79 ± 22.563.19 ± 25.57
Global Health Status Scale: Change at Cycle 234.03 ± 23.854.07 ± 27.18
Global Health Status Scale: Change at Cycle 244.24 ± 22.662.92 ± 30.58
Global Health Status Scale: Change at Cycle 253.59 ± 22.388.10 ± 25.39
Global Health Status Scale: Change at Cycle 267.27 ± 24.555.47 ± 26.91
Global Health Status Scale: Change at Cycle 277.54 ± 23.191.72 ± 28.38
Global Health Status Scale: Change at Cycle 284.49 ± 22.694.81 ± 28.98
Global Health Status Scale: Change at PT Visit 1-7.24 ± 27.24-6.14 ± 24.97
Global Health Status Scale: Change at PT Visit 2-2.72 ± 27.46-5.68 ± 26.57
Role Functional Scale: Cycle 1 (Baseline)77.06 ± 27.0279.33 ± 25.12
Role Functional Scale: Change at Cycle 2-3.78 ± 24.99-2.82 ± 24.35
Role Functional Scale: Change at Cycle 3-3.62 ± 25.96-4.55 ± 28.00
Role Functional Scale: Change at Cycle 4-4.64 ± 27.69-5.99 ± 26.87
Role Functional Scale: Change at Cycle 5-4.72 ± 27.68-7.41 ± 27.25
Role Functional Scale: Change at Cycle 6-6.13 ± 28.94-6.03 ± 28.51
Role Functional Scale: Change at Cycle 7-4.82 ± 29.75-5.34 ± 26.31
Role Functional Scale: Change at Cycle 8-1.85 ± 28.87-2.38 ± 26.41
Role Functional Scale: Change at Cycle 9-1.19 ± 28.57-2.47 ± 27.29
Role Functional Scale: Change at Cycle 10-1.79 ± 28.100.90 ± 25.97
Role Functional Scale: Change at Cycle 11-0.78 ± 28.34-2.69 ± 24.94
Role Functional Scale: Change at Cycle 12-1.05 ± 27.280.24 ± 24.07
Role Functional Scale: Change at Cycle 13-2.01 ± 26.61-2.40 ± 24.91
Role Functional Scale: Change at Cycle 14-0.86 ± 27.27-1.31 ± 25.66
Role Functional Scale: Change at Cycle 15-1.03 ± 27.51-3.23 ± 25.40
Role Functional Scale: Change at Cycle 16-3.16 ± 28.73-2.35 ± 25.48
Role Functional Scale: Change at Cycle 17-1.04 ± 26.69-3.38 ± 25.88
Role Functional Scale: Change at Cycle 18-0.16 ± 27.100.23 ± 26.05
Role Functional Scale: Change at Cycle 191.04 ± 27.55-0.25 ± 23.48
Role Functional Scale: Change at Cycle 20-1.19 ± 30.040.79 ± 23.46
Role Functional Scale: Change at Cycle 21-0.84 ± 28.980.00 ± 27.47
Role Functional Scale: Change at Cycle 22-2.24 ± 27.961.06 ± 22.63
Role Functional Scale: Change at Cycle 23-3.44 ± 30.111.14 ± 25.01
Role Functional Scale: Change at Cycle 24-4.44 ± 29.732.08 ± 24.22
Role Functional Scale: Change at Cycle 25-3.53 ± 29.214.63 ± 26.91
Role Functional Scale: Change at Cycle 26-1.36 ± 28.020.52 ± 26.60
Role Functional Scale: Change at Cycle 27-1.55 ± 30.82-4.02 ± 29.77
Role Functional Scale: Change at Cycle 28-0.42 ± 27.86-3.85 ± 29.56
Role Functional Scale: Change at PT Visit 1-14.61 ± 30.41-9.49 ± 28.64
Role Functional Scale: Change at PT Visit 2-10.73 ± 31.94-15.45 ± 31.82
Social Functional Scale: Cycle 1 (Baseline)77.96 ± 24.0975.90 ± 24.69
Social Functional Scale: Change at Cycle 2-3.45 ± 24.07-0.44 ± 23.09
Social Functional Scale: Change at Cycle 3-4.62 ± 25.25-2.07 ± 25.35
Social Functional Scale: Change at Cycle 4-2.59 ± 25.08-1.70 ± 26.58
Social Functional Scale: Change at Cycle 5-5.54 ± 27.03-3.26 ± 27.24
Social Functional Scale: Change at Cycle 6-5.72 ± 27.87-1.04 ± 27.20
Social Functional Scale: Change at Cycle 7-2.69 ± 27.13-0.15 ± 26.00
Social Functional Scale: Change at Cycle 8-1.72 ± 26.931.08 ± 26.49
Social Functional Scale: Change at Cycle 90.56 ± 27.590.77 ± 25.11
Social Functional Scale: Change at Cycle 10-0.81 ± 27.312.31 ± 25.75
Social Functional Scale: Change at Cycle 110.58 ± 27.351.94 ± 24.39
Social Functional Scale: Change at Cycle 120.52 ± 28.592.40 ± 24.70
Social Functional Scale: Change at Cycle 130.83 ± 25.312.10 ± 25.73
Social Functional Scale: Change at Cycle 141.98 ± 26.712.12 ± 24.89
Social Functional Scale: Change at Cycle 151.79 ± 27.240.00 ± 27.08
Social Functional Scale: Change at Cycle 16-0.72 ± 25.760.39 ± 25.84
Social Functional Scale: Change at Cycle 17-0.45 ± 26.511.58 ± 24.39
Social Functional Scale: Change at Cycle 18-0.98 ± 25.992.11 ± 26.42
Social Functional Scale: Change at Cycle 192.26 ± 26.563.28 ± 21.53
Social Functional Scale: Change at Cycle 201.59 ± 27.090.79 ± 22.88
Social Functional Scale: Change at Cycle 211.27 ± 28.095.86 ± 22.00
Social Functional Scale: Change at Cycle 221.24 ± 27.722.84 ± 24.16
Social Functional Scale: Change at Cycle 236.08 ± 27.321.89 ± 22.51
Social Functional Scale: Change at Cycle 245.83 ± 25.644.17 ± 24.39
Social Functional Scale: Change at Cycle 251.60 ± 27.272.78 ± 23.40
Social Functional Scale: Change at Cycle 263.74 ± 26.191.56 ± 24.45
Social Functional Scale: Change at Cycle 275.81 ± 24.37-1.72 ± 26.85
Social Functional Scale: Change at Cycle 286.25 ± 23.48-0.64 ± 24.26
Social Functional Scale: Change at PT Visit 1-9.13 ± 26.47-3.80 ± 28.74
Social Functional Scale: Change at PT Visit 2-5.45 ± 28.49-8.48 ± 28.98
Insomnia Symptom Scale: Cycle 1 (Baseline)22.94 ± 28.0025.41 ± 28.81
Insomnia Symptom Scale: Change at Cycle 2-0.69 ± 26.82-0.39 ± 28.27
Insomnia Symptom Scale: Change at Cycle 3-3.53 ± 27.03-3.48 ± 30.14
Insomnia Symptom Scale: Change at Cycle 4-2.88 ± 28.14-3.62 ± 30.40
Insomnia Symptom Scale: Change at Cycle 5-2.21 ± 29.27-2.66 ± 30.17
Insomnia Symptom Scale: Change at Cycle 6-2.94 ± 28.63-5.58 ± 32.53
Insomnia Symptom Scale: Change at Cycle 7-4.56 ± 28.42-4.82 ± 32.98
Insomnia Symptom Scale: Change at Cycle 8-6.13 ± 27.72-6.45 ± 30.75
Insomnia Symptom Scale: Change at Cycle 9-8.97 ± 25.69-6.12 ± 30.32
Insomnia Symptom Scale: Change at Cycle 10-8.24 ± 26.69-4.42 ± 28.79
Insomnia Symptom Scale: Change at Cycle 11-8.97 ± 28.19-5.81 ± 27.69
Insomnia Symptom Scale: Change at Cycle 12-8.81 ± 27.67-6.43 ± 26.49
Insomnia Symptom Scale: Change at Cycle 13-10.17 ± 26.71-5.11 ± 24.29
Insomnia Symptom Scale: Change at Cycle 14-9.14 ± 26.84-7.84 ± 24.45
Insomnia Symptom Scale: Change at Cycle 15-9.74 ± 28.89-5.10 ± 21.59
Insomnia Symptom Scale: Change at Cycle 16-8.91 ± 26.14-4.31 ± 26.62
Insomnia Symptom Scale: Change at Cycle 17-11.01 ± 26.62-5.41 ± 26.48
Insomnia Symptom Scale: Change at Cycle 18-8.82 ± 28.12-8.45 ± 20.09
Insomnia Symptom Scale: Change at Cycle 19-11.46 ± 29.35-7.58 ± 22.49
Insomnia Symptom Scale: Change at Cycle 20-10.32 ± 27.37-5.29 ± 25.55
Insomnia Symptom Scale: Change at Cycle 21-11.81 ± 27.24-4.94 ± 27.02
Insomnia Symptom Scale: Change at Cycle 22-10.95 ± 31.46-7.80 ± 19.92
Insomnia Symptom Scale: Change at Cycle 23-10.58 ± 34.82-6.06 ± 23.04
Insomnia Symptom Scale: Change at Cycle 24-9.44 ± 31.94-7.50 ± 21.99
Insomnia Symptom Scale: Change at Cycle 25-10.26 ± 28.42-8.33 ± 26.87
Insomnia Symptom Scale: Change at Cycle 26-9.52 ± 32.63-4.17 ± 20.30
Insomnia Symptom Scale: Change at Cycle 27-13.18 ± 30.11-4.60 ± 19.36
Insomnia Symptom Scale: Change at Cycle 28-11.67 ± 31.62-1.28 ± 22.07
Insomnia Symptom Scale: Change at PT Visit 12.81 ± 29.19-1.32 ± 30.81
Insomnia Symptom Scale: Change at PT Visit 25.67 ± 29.233.03 ± 31.13
SecondaryChange From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score

The EORTC QLQ-STO22 is a gastric cancer quality of life questionnaire. There are 22 questions concerning disease, treatment related symptoms, side effects, dysphagia, nutritional aspects, and questions about the emotional problems of gastric cancer (dysphagia, pain, reflux, eating restrictions, anxiety, dry mouth, body image, and hair loss). The questions are grouped into five scales and 4 single items which are related to the symptoms of the disease. Most questions used 4-point scale (1 'Not at all' to 4 'Very much'; 1 question was a yes or no answer). A linear transformation was used to standardize all scores and single-items to a scale of 0 to 100; higher score=better level of functioning or greater degree of symptoms. A positive value means an increase, while a negative values means a decrease, in score at the indicated time-point relative to the score at baseline (Cycle 1, Day 1).

Time frame:
Day 1 of each 21-day treatment cycle up to 28 and 60-90 days (post-treatment [PT] monitoring visits 1 and 2, respectively) after Day 1 of last treatment cycle (up to approximately 3.5 years)
Reported as:
Mean · score on a scale
Change From Baseline in EORTC QLQ-Gastric Cancer Module (EORTC QLQ-STO22) Score
score on a scalePertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
Anxiety: Cycle 1 (Baseline)40.10 ± 25.8540.48 ± 25.32
Anxiety: Change at Cycle 2-2.58 ± 21.72-4.11 ± 21.19
Anxiety: Change at Cycle 3-4.14 ± 22.45-3.87 ± 23.19
Anxiety: Change at Cycle 4-4.52 ± 23.01-7.25 ± 23.16
Anxiety: Change at Cycle 5-4.10 ± 22.94-7.39 ± 24.36
Anxiety: Change at Cycle 6-4.54 ± 23.97-8.42 ± 25.21
Anxiety: Change at Cycle 7-6.40 ± 24.00-10.40 ± 24.37
Anxiety: Change at Cycle 8-9.00 ± 23.17-11.92 ± 24.50
Anxiety: Change at Cycle 9-10.09 ± 23.30-11.43 ± 23.24
Anxiety: Change at Cycle 10-11.17 ± 25.05-12.64 ± 22.09
Anxiety: Change at Cycle 11-10.78 ± 23.47-12.09 ± 21.84
Anxiety: Change at Cycle 12-12.62 ± 26.24-13.16 ± 23.11
Anxiety: Change at Cycle 13-13.32 ± 25.93-13.33 ± 22.47
Anxiety: Change at Cycle 14-14.32 ± 26.49-12.43 ± 23.59
Anxiety: Change at Cycle 15-13.42 ± 26.64-10.65 ± 25.74
Anxiety: Change at Cycle 16-12.75 ± 26.87-12.57 ± 23.89
Anxiety: Change at Cycle 17-13.41 ± 27.30-12.79 ± 21.01
Anxiety: Change at Cycle 18-13.53 ± 28.05-12.38 ± 22.90
Anxiety: Change at Cycle 19-14.50 ± 27.41-12.48 ± 20.08
Anxiety: Change at Cycle 20-15.34 ± 29.21-12.37 ± 23.73
Anxiety: Change at Cycle 21-16.03 ± 28.84-14.47 ± 25.00
Anxiety: Change at Cycle 22-13.30 ± 30.77-15.46 ± 23.83
Anxiety: Change at Cycle 23-17.28 ± 30.64-14.47 ± 29.55
Anxiety: Change at Cycle 24-16.11 ± 30.65-17.09 ± 23.76
Anxiety: Change at Cycle 25-16.03 ± 29.47-17.78 ± 23.68
Anxiety: Change at Cycle 26-19.73 ± 30.28-13.26 ± 22.11
Anxiety: Change at Cycle 27-21.71 ± 29.89-12.70 ± 20.67
Anxiety: Change at Cycle 28-22.51 ± 29.34-12.89 ± 22.38
Anxiety: Change at PT Visit 1-0.73 ± 25.18-4.73 ± 27.21
Anxiety: Change at PT Visit 2-4.04 ± 28.24-3.98 ± 25.02
Body Image: Cycle 1 (Baseline)23.53 ± 28.4023.68 ± 27.47
Body Image: Change at Cycle 21.33 ± 28.191.20 ± 26.44
Body Image: Change at Cycle 31.48 ± 29.063.88 ± 28.03
Body Image: Change at Cycle 44.20 ± 28.511.15 ± 27.19
Body Image: Change at Cycle 52.86 ± 30.911.06 ± 25.74
Body Image: Change at Cycle 60.75 ± 30.112.78 ± 28.48
Body Image: Change at Cycle 7-0.56 ± 28.940.29 ± 25.53
Body Image: Change at Cycle 8-1.74 ± 29.830.00 ± 26.30
Body Image: Change at Cycle 9-3.58 ± 28.74-0.69 ± 24.52
Body Image: Change at Cycle 10-5.07 ± 30.15-3.25 ± 24.55
Body Image: Change at Cycle 11-4.62 ± 30.24-1.53 ± 25.46
Body Image: Change at Cycle 12-5.31 ± 31.92-2.66 ± 27.04
Body Image: Change at Cycle 13-4.73 ± 30.23-2.73 ± 25.99
Body Image: Change at Cycle 14-5.43 ± 29.70-4.62 ± 24.05
Body Image: Change at Cycle 15-3.08 ± 30.63-2.43 ± 27.03
Body Image: Change at Cycle 16-1.74 ± 32.99-1.19 ± 26.10
Body Image: Change at Cycle 17-2.70 ± 32.76-2.28 ± 21.75
Body Image: Change at Cycle 18-2.64 ± 30.44-5.71 ± 23.38
Body Image: Change at Cycle 19-2.81 ± 33.57-5.21 ± 20.76
Body Image: Change at Cycle 20-3.97 ± 30.79-5.38 ± 22.74
Body Image: Change at Cycle 211.69 ± 30.15-8.18 ± 26.07
Body Image: Change at Cycle 22-1.49 ± 32.01-10.87 ± 22.28
Body Image: Change at Cycle 23-5.82 ± 24.35-8.53 ± 29.18
Body Image: Change at Cycle 24-0.56 ± 31.25-11.11 ± 23.36
Body Image: Change at Cycle 25-3.21 ± 28.97-11.43 ± 24.18
Body Image: Change at Cycle 26-4.76 ± 29.66-6.45 ± 18.09
Body Image: Change at Cycle 270.78 ± 24.65-7.14 ± 21.00
Body Image: Change at Cycle 28-4.27 ± 26.69-4.00 ± 24.19
Body Image: Change at PT Visit 12.48 ± 31.573.42 ± 29.31
Body Image: Change at PT Visit 22.36 ± 35.406.35 ± 27.38
Dry Mouth: Cycle 1 (Baseline)21.80 ± 25.0723.32 ± 26.79
Dry Mouth: Change at Cycle 27.72 ± 28.703.00 ± 25.43
Dry Mouth: Change at Cycle 36.10 ± 28.654.87 ± 27.33
Dry Mouth: Change at Cycle 44.76 ± 29.402.66 ± 31.06
Dry Mouth: Change at Cycle 52.47 ± 29.672.57 ± 28.68
Dry Mouth: Change at Cycle 62.96 ± 30.141.19 ± 27.65
Dry Mouth: Change at Cycle 7-1.96 ± 28.820.44 ± 28.54
Dry Mouth: Change at Cycle 8-2.43 ± 28.68-2.66 ± 26.27
Dry Mouth: Change at Cycle 9-3.70 ± 25.70-4.32 ± 24.74
Dry Mouth: Change at Cycle 10-6.27 ± 25.04-3.46 ± 23.53
Dry Mouth: Change at Cycle 11-7.69 ± 25.46-1.96 ± 26.56
Dry Mouth: Change at Cycle 12-8.18 ± 24.22-4.35 ± 26.36
Dry Mouth: Change at Cycle 13-9.69 ± 24.08-8.48 ± 26.50
Dry Mouth: Change at Cycle 14-8.33 ± 24.60-3.63 ± 29.78
Dry Mouth: Change at Cycle 15-7.89 ± 22.20-7.29 ± 26.58
Dry Mouth: Change at Cycle 16-6.32 ± 24.44-8.33 ± 27.80
Dry Mouth: Change at Cycle 17-7.44 ± 23.12-3.20 ± 24.32
Dry Mouth: Change at Cycle 18-5.56 ± 24.86-8.10 ± 28.62
Dry Mouth: Change at Cycle 19-5.90 ± 24.18-7.69 ± 25.53
Dry Mouth: Change at Cycle 20-6.35 ± 26.62-9.68 ± 27.25
Dry Mouth: Change at Cycle 21-7.17 ± 24.27-9.43 ± 20.02
Dry Mouth: Change at Cycle 22-3.98 ± 26.29-8.70 ± 23.76
Dry Mouth: Change at Cycle 23-7.94 ± 23.73-3.88 ± 25.42
Dry Mouth: Change at Cycle 24-6.67 ± 25.15-9.40 ± 28.56
Dry Mouth: Change at Cycle 25-8.33 ± 22.75-9.52 ± 28.66
Dry Mouth: Change at Cycle 26-2.72 ± 23.41-7.53 ± 26.82
Dry Mouth: Change at Cycle 27-6.98 ± 21.28-7.14 ± 27.75
Dry Mouth: Change at Cycle 28-8.55 ± 21.24-8.00 ± 22.11
Dry Mouth: Change at PT Visit 10.19 ± 28.702.38 ± 31.58
Dry Mouth: Change at PT Visit 2-1.35 ± 30.091.89 ± 25.95
Dysphagia: Cycle 1 (Baseline)16.29 ± 21.4614.15 ± 18.93
Dysphagia: Change at Cycle 2-2.27 ± 17.64-0.53 ± 19.32
Dysphagia: Change at Cycle 3-3.39 ± 18.57-2.15 ± 19.67
Dysphagia: Change at Cycle 4-2.94 ± 18.93-1.08 ± 18.79
Dysphagia: Change at Cycle 5-3.22 ± 19.92-1.83 ± 18.99
Dysphagia: Change at Cycle 6-4.20 ± 18.99-2.25 ± 18.70
Dysphagia: Change at Cycle 7-4.83 ± 20.56-1.97 ± 19.94
Dysphagia: Change at Cycle 8-5.96 ± 18.80-3.29 ± 18.48
Dysphagia: Change at Cycle 9-6.17 ± 18.21-3.86 ± 18.49
Dysphagia: Change at Cycle 10-6.03 ± 17.37-4.61 ± 16.87
Dysphagia: Change at Cycle 11-6.25 ± 17.09-2.83 ± 17.03
Dysphagia: Change at Cycle 12-7.06 ± 17.65-4.19 ± 15.84
Dysphagia: Change at Cycle 13-6.93 ± 18.71-3.54 ± 17.61
Dysphagia: Change at Cycle 14-8.01 ± 18.53-4.95 ± 18.22
Dysphagia: Change at Cycle 15-6.45 ± 17.38-2.14 ± 18.69
Dysphagia: Change at Cycle 16-4.41 ± 18.29-3.70 ± 21.08
Dysphagia: Change at Cycle 17-5.36 ± 16.87-3.20 ± 14.99
Dysphagia: Change at Cycle 18-4.90 ± 16.44-3.33 ± 19.78
Dysphagia: Change at Cycle 19-4.40 ± 17.10-3.59 ± 14.31
Dysphagia: Change at Cycle 20-2.51 ± 16.21-3.76 ± 15.83
Dysphagia: Change at Cycle 21-3.80 ± 19.24-2.10 ± 17.84
Dysphagia: Change at Cycle 22-3.65 ± 20.41-4.83 ± 15.65
Dysphagia: Change at Cycle 23-4.23 ± 18.87-3.88 ± 17.63
Dysphagia: Change at Cycle 24-5.00 ± 18.35-3.70 ± 13.08
Dysphagia: Change at Cycle 25-5.98 ± 19.61-2.22 ± 16.79
Dysphagia: Change at Cycle 26-5.67 ± 20.43-2.87 ± 16.22
Dysphagia: Change at Cycle 27-5.68 ± 20.91-4.37 ± 12.22
Dysphagia: Change at Cycle 28-8.26 ± 19.86-3.56 ± 11.44
Dysphagia: Change at PT Visit 10.44 ± 24.152.83 ± 22.63
Dysphagia: Change at PT Visit 2-2.81 ± 24.403.25 ± 19.81
Eating Restrictions: Cycle 1 (Baseline)23.26 ± 21.7822.33 ± 20.22
Eating Restrictions: Change at Cycle 2-1.41 ± 19.36-1.54 ± 19.62
Eating Restrictions: Change at Cycle 3-1.04 ± 21.09-2.20 ± 20.94
Eating Restrictions: Change at Cycle 4-2.24 ± 20.81-1.39 ± 23.36
Eating Restrictions: Change at Cycle 5-1.39 ± 22.10-0.09 ± 23.31
Eating Restrictions: Change at Cycle 6-1.35 ± 22.77-3.32 ± 23.14
Eating Restrictions: Change at Cycle 7-2.45 ± 22.68-2.67 ± 21.66
Eating Restrictions: Change at Cycle 8-4.29 ± 22.70-5.56 ± 19.87
Eating Restrictions: Change at Cycle 9-6.99 ± 21.16-6.48 ± 19.69
Eating Restrictions: Change at Cycle 10-7.06 ± 21.32-5.89 ± 19.30
Eating Restrictions: Change at Cycle 11-8.22 ± 21.25-5.05 ± 19.98
Eating Restrictions: Change at Cycle 12-7.74 ± 21.16-6.34 ± 19.87
Eating Restrictions: Change at Cycle 13-8.55 ± 20.41-8.41 ± 19.57
Eating Restrictions: Change at Cycle 14-8.62 ± 19.16-8.58 ± 21.16
Eating Restrictions: Change at Cycle 15-6.85 ± 20.92-5.56 ± 21.21
Eating Restrictions: Change at Cycle 16-5.77 ± 22.01-6.94 ± 20.36
Eating Restrictions: Change at Cycle 17-5.56 ± 21.95-7.42 ± 17.76
Eating Restrictions: Change at Cycle 18-7.27 ± 20.40-6.90 ± 21.14
Eating Restrictions: Change at Cycle 19-7.03 ± 21.78-5.38 ± 18.07
Eating Restrictions: Change at Cycle 20-4.56 ± 21.03-4.44 ± 16.72
Eating Restrictions: Change at Cycle 21-5.80 ± 22.58-5.03 ± 19.97
Eating Restrictions: Change at Cycle 22-3.65 ± 21.79-6.16 ± 16.80
Eating Restrictions: Change at Cycle 23-3.70 ± 22.74-5.23 ± 20.25
Eating Restrictions: Change at Cycle 24-5.00 ± 20.77-7.91 ± 15.76
Eating Restrictions: Change at Cycle 25-5.77 ± 21.10-5.95 ± 16.61
Eating Restrictions: Change at Cycle 26-6.80 ± 21.22-2.42 ± 22.89
Eating Restrictions: Change at Cycle 27-5.62 ± 23.48-3.87 ± 10.26
Eating Restrictions: Change at Cycle 28-7.91 ± 21.79-5.00 ± 11.02
Eating Restrictions: Change at PT Visit 11.52 ± 24.480.94 ± 24.70
Eating Restrictions: Change at PT Visit 2-2.10 ± 25.320.94 ± 21.46
Hair Loss: Cycle 1 (Baseline)4.73 ± 13.284.04 ± 13.20
Hair Loss: Change at Cycle 20.20 ± 14.851.27 ± 16.59
Hair Loss: Change at Cycle 34.34 ± 17.514.52 ± 18.71
Hair Loss: Change at Cycle 45.40 ± 18.466.53 ± 20.99
Hair Loss: Change at Cycle 56.12 ± 19.387.18 ± 19.49
Hair Loss: Change at Cycle 66.93 ± 18.8710.07 ± 22.94
Hair Loss: Change at Cycle 75.72 ± 19.919.26 ± 22.92
Hair Loss: Change at Cycle 85.00 ± 18.967.38 ± 23.05
Hair Loss: Change at Cycle 92.38 ± 17.436.46 ± 21.06
Hair Loss: Change at Cycle 100.64 ± 16.884.22 ± 19.51
Hair Loss: Change at Cycle 11-0.10 ± 17.022.54 ± 17.51
Hair Loss: Change at Cycle 120.21 ± 19.701.96 ± 15.72
Hair Loss: Change at Cycle 130.36 ± 18.912.29 ± 15.46
Hair Loss: Change at Cycle 14-1.37 ± 17.591.83 ± 15.15
Hair Loss: Change at Cycle 15-0.39 ± 15.651.58 ± 12.65
Hair Loss: Change at Cycle 16-1.47 ± 17.471.42 ± 13.91
Hair Loss: Change at Cycle 17-1.07 ± 17.750.23 ± 12.57
Hair Loss: Change at Cycle 18-1.68 ± 17.58-0.71 ± 13.14
Hair Loss: Change at Cycle 19-0.90 ± 18.120.51 ± 14.12
Hair Loss: Change at Cycle 20-0.20 ± 19.21-1.61 ± 12.70
Hair Loss: Change at Cycle 21-1.07 ± 19.43-1.57 ± 8.81
Hair Loss: Change at Cycle 22-0.50 ± 16.66-3.26 ± 11.98
Hair Loss: Change at Cycle 23-0.54 ± 16.79-1.19 ± 11.28
Hair Loss: Change at Cycle 24-1.39 ± 17.441.71 ± 16.13
Hair Loss: Change at Cycle 25-1.96 ± 18.75-0.95 ± 9.85
Hair Loss: Change at Cycle 26-1.02 ± 19.37-0.54 ± 10.08
Hair Loss: Change at Cycle 27-3.10 ± 15.96-0.60 ± 10.62
Hair Loss: Change at Cycle 28-4.70 ± 20.57-1.33 ± 10.67
Hair Loss: Change at PT Visit 14.98 ± 19.734.51 ± 20.39
Hair Loss: Change at PT Visit 215.82 ± 25.3522.22 ± 30.81
Pain: Cycle 1 (Baseline)26.48 ± 21.3426.47 ± 20.70
Pain: Change at Cycle 2-4.63 ± 20.30-5.86 ± 19.15
Pain: Change at Cycle 3-6.96 ± 20.37-5.86 ± 20.68
Pain: Change at Cycle 4-6.45 ± 21.47-7.48 ± 21.23
Pain: Change at Cycle 5-7.28 ± 20.95-6.89 ± 22.10
Pain: Change at Cycle 6-7.24 ± 20.84-7.22 ± 21.62
Pain: Change at Cycle 7-9.52 ± 21.18-6.62 ± 21.63
Pain: Change at Cycle 8-10.53 ± 21.62-8.16 ± 20.11
Pain: Change at Cycle 9-10.08 ± 19.60-8.98 ± 20.29
Pain: Change at Cycle 10-10.63 ± 19.23-8.59 ± 20.38
Pain: Change at Cycle 11-11.65 ± 19.35-8.01 ± 18.97
Pain: Change at Cycle 12-11.76 ± 19.87-7.19 ± 19.11
Pain: Change at Cycle 13-11.92 ± 18.93-9.24 ± 19.79
Pain: Change at Cycle 14-11.66 ± 19.51-9.82 ± 19.91
Pain: Change at Cycle 15-11.15 ± 18.16-8.51 ± 20.94
Pain: Change at Cycle 16-8.72 ± 18.02-10.52 ± 21.30
Pain: Change at Cycle 17-8.88 ± 18.17-9.93 ± 17.27
Pain: Change at Cycle 18-8.31 ± 18.33-11.19 ± 18.16
Pain: Change at Cycle 19-6.63 ± 17.25-10.38 ± 14.51
Pain: Change at Cycle 20-5.72 ± 19.98-10.35 ± 16.65
Pain: Change at Cycle 21-8.19 ± 18.27-7.55 ± 16.77
Pain: Change at Cycle 22-9.08 ± 18.10-9.42 ± 16.72
Pain: Change at Cycle 23-9.66 ± 20.75-8.53 ± 19.96
Pain: Change at Cycle 24-9.86 ± 21.56-8.76 ± 15.53
Pain: Change at Cycle 25-10.58 ± 19.88-8.10 ± 18.69
Pain: Change at Cycle 26-9.01 ± 17.99-9.41 ± 17.58
Pain: Change at Cycle 27-12.02 ± 17.28-9.23 ± 14.58
Pain: Change at Cycle 28-11.54 ± 18.20-7.33 ± 13.46
Pain: Change at PT Visit 1-1.70 ± 23.07-2.99 ± 23.86
Pain: Change at PT Visit 2-7.49 ± 24.09-0.03 ± 22.04
Reflux Symptoms: Cycle 1 (Baseline)16.68 ± 19.0317.34 ± 18.31
Reflux Symptoms: Change at Cycle 2-0.13 ± 16.33-1.99 ± 18.03
Reflux Symptoms: Change at Cycle 3-0.52 ± 18.95-2.28 ± 19.53
Reflux Symptoms: Change at Cycle 4-0.98 ± 19.18-1.90 ± 19.93
Reflux Symptoms: Change at Cycle 5-1.92 ± 18.98-1.72 ± 20.10
Reflux Symptoms: Change at Cycle 6-2.90 ± 20.42-3.59 ± 19.04
Reflux Symptoms: Change at Cycle 7-4.18 ± 18.36-3.20 ± 20.21
Reflux Symptoms: Change at Cycle 8-4.96 ± 19.39-5.74 ± 19.53
Reflux Symptoms: Change at Cycle 9-5.02 ± 18.97-5.18 ± 19.81
Reflux Symptoms: Change at Cycle 10-6.12 ± 17.81-6.48 ± 18.55
Reflux Symptoms: Change at Cycle 11-6.44 ± 18.74-6.03 ± 18.07
Reflux Symptoms: Change at Cycle 12-4.82 ± 18.00-7.49 ± 16.99
Reflux Symptoms: Change at Cycle 13-6.42 ± 17.09-6.77 ± 18.19
Reflux Symptoms: Change at Cycle 14-5.39 ± 18.24-7.37 ± 17.45
Reflux Symptoms: Change at Cycle 15-5.00 ± 16.66-4.98 ± 18.72
Reflux Symptoms: Change at Cycle 16-3.07 ± 18.39-4.89 ± 22.31
Reflux Symptoms: Change at Cycle 17-3.35 ± 18.38-4.57 ± 20.44
Reflux Symptoms: Change at Cycle 18-2.94 ± 18.36-6.51 ± 20.33
Reflux Symptoms: Change at Cycle 19-2.43 ± 16.38-6.15 ± 18.43
Reflux Symptoms: Change at Cycle 20-1.85 ± 18.32-5.38 ± 18.63
Reflux Symptoms: Change at Cycle 21-1.83 ± 18.44-4.19 ± 17.73
Reflux Symptoms: Change at Cycle 22-3.81 ± 19.30-7.00 ± 19.65
Reflux Symptoms: Change at Cycle 23-5.11 ± 17.03-6.98 ± 19.70
Reflux Symptoms: Change at Cycle 24-4.07 ± 19.30-7.98 ± 18.19
Reflux Symptoms: Change at Cycle 25-5.56 ± 18.86-5.71 ± 16.69
Reflux Symptoms: Change at Cycle 26-4.99 ± 20.67-4.30 ± 21.98
Reflux Symptoms: Change at Cycle 27-7.75 ± 20.51-6.75 ± 16.10
Reflux Symptoms: Change at Cycle 28-7.12 ± 18.64-4.44 ± 11.56
Reflux Symptoms: Change at PT Visit 10.88 ± 20.01-0.45 ± 22.92
Reflux Symptoms: Change at PT Visit 20.56 ± 18.67-1.47 ± 22.28
Taste: Cycle 1 (Baseline)13.79 ± 23.9916.22 ± 25.49
Taste: Change at Cycle 212.09 ± 28.786.61 ± 26.94
Taste: Change at Cycle 316.72 ± 32.119.99 ± 30.16
Taste: Change at Cycle 418.43 ± 34.7011.07 ± 31.93
Taste: Change at Cycle 517.61 ± 32.9311.85 ± 30.25
Taste: Change at Cycle 617.97 ± 31.2011.82 ± 32.21
Taste: Change at Cycle 716.25 ± 33.519.19 ± 31.09
Taste: Change at Cycle 811.64 ± 29.813.29 ± 28.13
Taste: Change at Cycle 99.22 ± 28.251.73 ± 26.30
Taste: Change at Cycle 107.93 ± 26.411.63 ± 28.79
Taste: Change at Cycle 114.96 ± 26.722.61 ± 26.91
Taste: Change at Cycle 125.27 ± 24.820.24 ± 24.66
Taste: Change at Cycle 134.08 ± 25.53-0.91 ± 25.33
Taste: Change at Cycle 140.49 ± 25.66-5.28 ± 24.37
Taste: Change at Cycle 153.08 ± 24.36-1.04 ± 26.25
Taste: Change at Cycle 165.51 ± 27.90-3.57 ± 20.71
Taste: Change at Cycle 174.80 ± 24.96-3.65 ± 23.28
Taste: Change at Cycle 183.59 ± 23.87-4.29 ± 23.34
Taste: Change at Cycle 193.13 ± 25.17-4.62 ± 15.45
Taste: Change at Cycle 205.56 ± 27.78-3.76 ± 18.21
Taste: Change at Cycle 216.33 ± 27.26-5.03 ± 17.78
Taste: Change at Cycle 229.45 ± 30.04-4.35 ± 16.64
Taste: Change at Cycle 238.99 ± 30.060.00 ± 23.00
Taste: Change at Cycle 247.78 ± 28.37-5.13 ± 19.55
Taste: Change at Cycle 253.21 ± 28.97-4.76 ± 18.33
Taste: Change at Cycle 264.08 ± 34.45-3.23 ± 21.70
Taste: Change at Cycle 274.65 ± 29.62-3.57 ± 20.96
Taste: Change at Cycle 283.42 ± 21.35-6.67 ± 25.46
Taste: Change at PT Visit 112.76 ± 34.599.06 ± 33.56
Taste: Change at PT Visit 28.42 ± 31.356.67 ± 28.64
SecondaryMaximum Serum Concentration (Cmax) of Pertuzumab
Time frame:
Post-dose (0.5 hour after end of 30-60 minutes infusion) on Day 1 of Cycles 1, 2, 4, and 8 (1 cycle = 21 days)
Reported as:
Mean · micrograms per milliliter (μg/mL)
Maximum Serum Concentration (Cmax) of Pertuzumab
micrograms per milliliter (μg/mL)Pertuzumab + Trastuzumab + Chemotherapy
Cycle 1258 ± 90.3
Cycle 2288 ± 83.7
Cycle 4341 ± 111
Cycle 8371 ± 127
SecondaryCmax of Trastuzumab
Time frame:
Post-dose (0.5 hour after end of 30-60 minutes infusion) on Day 1 of Cycles 1, 2, 4, and 8 (1 cycle = 21 days)
Reported as:
Mean · μg/mL
Cmax of Trastuzumab
μg/mLPertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
Cycle 1142 ± 86.8139 ± 58.6
Cycle 2120 ± 46.6120 ± 44.3
Cycle 4127 ± 50.9129 ± 58.1
Cycle 8130 ± 50.8147 ± 90.2
SecondaryMinimum Serum Concentration (Cmin) of Pertuzumab
Time frame:
Pre-dose (0-6 hours before infusion) on Day 1 of Cycles 1, 2, 3, 4, 6, and 8 (1 cycle = 21 days)
Reported as:
Mean · μg/mL
Minimum Serum Concentration (Cmin) of Pertuzumab
μg/mLPertuzumab + Trastuzumab + Chemotherapy
Cycle 1NA ± NA
Cycle 242.4 ± 24.8
Cycle 374.0 ± 40.9
Cycle 490.4 ± 42.4
Cycle 6114 ± 51.8
Cycle 8142 ± 67.9
SecondaryCmin of Trastuzumab
Time frame:
Pre-dose (0-6 hours before infusion) on Day 1 of Cycles 1, 2, 3, 4, 6, and 8 (1 cycle = 21 days)
Reported as:
Mean · μg/mL
Cmin of Trastuzumab
μg/mLPertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
Cycle 1NA ± NANA ± NA
Cycle 215.4 ± 11.317.2 ± 15.4
Cycle 319.9 ± 13.420.7 ± 15.2
Cycle 422.9 ± 12.724.1 ± 19.0
Cycle 626.3 ± 14.829.8 ± 21.9
Cycle 832.7 ± 15.037.4 ± 20.3

Adverse events

Collected over From Baseline until end of post-treatment follow-up (up to 70 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pertuzumab + Trastuzumab + Chemotherapy299/385 (77.7%)178/385 (46.2%)373/385 (96.9%)
Placebo + Trastuzumab + Chemotherapy318/388 (82%)156/388 (40.2%)376/388 (96.9%)
Most frequent serious events
Showing 10 of 191
Most frequent serious events
EventPertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
DiarrhoeaGastrointestinal disorders17/38520/388
Decreased appetiteMetabolism and nutrition disorders17/3859/388
AnaemiaBlood and lymphatic system disorders8/38516/388
PneumoniaInfections and infestations14/38514/388
VomitingGastrointestinal disorders7/38513/388
DehydrationMetabolism and nutrition disorders9/3859/388
Febrile neutropeniaBlood and lymphatic system disorders6/3859/388
DeathGeneral disorders8/3859/388
SepsisInfections and infestations8/3852/388
NauseaGastrointestinal disorders7/3857/388
Most frequent other events
Showing 10 of 49
Most frequent other events
EventPertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + Chemotherapy
DiarrhoeaGastrointestinal disorders230/385125/388
NauseaGastrointestinal disorders224/385218/388
NeutropeniaBlood and lymphatic system disorders200/385202/388
Decreased appetiteMetabolism and nutrition disorders172/385158/388
AnaemiaBlood and lymphatic system disorders159/385142/388
VomitingGastrointestinal disorders147/385122/388
FatigueGeneral disorders144/385123/388
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders86/385100/388
ConstipationGastrointestinal disorders56/38584/388
StomatitisGastrointestinal disorders81/38569/388

Baseline characteristics

The Intent-to-Treat (ITT) population included all randomized participants regardless of whether treatment was actually received, with participants grouped according to the treatment assigned at randomization.

Age, Continuous
Age, Continuous(Years)Pertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + ChemotherapyTotal
Mean60.9 ± 11.360.1 ± 10.760.5 ± 11.0
Sex: Female, Male
Sex: Female, Male(Participants)Pertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + ChemotherapyTotal
Female9469163
Male294323617
Geographic Region
Geographic Region(Participants)Pertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + ChemotherapyTotal
Asia (excluding Japan)143146289
Japan404080
North America/Western Europe/Australia133133266
South America/Eastern Europe7273145
Prior Gastrectomy
Prior Gastrectomy(Participants)Pertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + ChemotherapyTotal
Prior Gastrectomy105102207
No Prior Gastrectomy283290573
Human Epidermal Growth Factor Receptor 2 (HER2) Status
Human Epidermal Growth Factor Receptor 2 (HER2) Status(Participants)Pertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + ChemotherapyTotal
IHC 2+/ISH+129130259
IHC 3+259262521
Measurability of Disease, per RECIST v1.1
Measurability of Disease, per RECIST v1.1(Participants)Pertuzumab + Trastuzumab + ChemotherapyPlacebo + Trastuzumab + ChemotherapyTotal
Measurable Disease351352703
Non-Measurable Evaluable Disease Only374077
08

Study locations

172 sites
  • Florida Cancer Specialists - SCRI; Pharmacy
    Fort Myers, Florida 33901, United States
  • University Of Chicago Medical Center; Section Of Hematology/Oncology
    Chicago, Illinois 60637, United States
  • Indiana University Health; Goshen Center for Cancer Care
    Goshen, Indiana 46526, United States
  • Comprehensive Cancer Centers of Nevada - Eastern Avenue
    Las Vegas, Nevada 89169, United States
  • New York Oncology Hematology, P.C.
    Albany, New York 12206, United States
  • Queens Medical Associates
    Fresh Meadows, New York 11366, United States
  • Weill Medical College of Cornell University; Division of Hematology & Medical Oncology
    New York, New York 10065, United States
  • Oncology Hematology Care
    Cincinnati, Ohio 45219, United States
  • Medical University of South Carolina; Hollings Cancer Center
    Charleston, South Carolina 29425, United States
  • Tennessee Oncology PLLC - Nashville (20th Ave)
    Nashville, Tennessee 37203, United States
  • Royal Brisbane Womens Hosp; Division of Oncology
    Herston, Queensland 4029, Australia
  • Monash Medical Centre; Oncology
    Clayton, Victoria 3168, Australia
  • Austin Health; Cancer Clinical Trial Centre
    Heidelberg, Victoria 3084, Australia
  • Sir Charles Gairdner Hospital; Medical Oncology
    Perth, Western Australia 6009, Australia
  • Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt.
    Salzburg, 5020, Austria
  • Krankenhaus St. Vinzenz Der Barmherzigen Schwestern Zams; Abt. Für Innere Medizin
    Zams, 6511, Austria
  • Cliniques Universitaires St-Luc
    Bruxelles, 1200, Belgium
  • Clinicas Oncologicas Integradas - COI
    Rio De Janeiro, RJ 22290-160, Brazil
  • Hospital Nossa Senhora da Conceicao
    Porto Alegre, RS 91350-200, Brazil
  • Hospital das Clinicas - UFRGS
    Porto Alegre, RS, Brazil
  • Centro de Pesquisas Oncologicas - CEPON
    Florianopolis, SC 88034-000, Brazil
  • Hospital Sirio Libanes; Centro de Oncologia
    Sao Paulo, SP 01308-050, Brazil
  • Clinica de Oncologia Medica
    Sao Paulo, SP 01406100, Brazil
  • Hospital A. C. Camargo; Oncologia
    Sao Paulo, SP 01509-010, Brazil
  • Universidade Federal de Sao Paulo - UNIFESP*X
    Sao Paulo, SP 22793-080, Brazil
  • Complex Oncological Center - Plovdiv, EOOD
    Plovdiv, 4004, Bulgaria
  • MHAT Serdika
    Sofia, 1301, Bulgaria
  • SHATOD Dr. Marko Antonov Markov-Varna, EOOD; Department of Medicinall Onchotherapy and Palliative
    Varna, 9010, Bulgaria
  • Hamilton Health Sciences - Juravinski Cancer Centre
    Hamilton, Ontario L8V 5C2, Canada
  • London Regional Cancer Centre
    London, Ontario N6A 4L6, Canada
  • Health Sciences North
    Sudbury, Ontario P3E 5J1, Canada
  • Toronto East General Hospital; Haematology/Oncology
    Toronto, Ontario M4C 3E7, Canada
  • Sunnybrook Health Science Centre
    Toronto, Ontario M4N 3M5, Canada
  • Mount Sinai Hospital; Oncology
    Toronto, Ontario M5G 1X5, Canada
  • McGill University; Glen Site; Oncology
    Montreal, Quebec H4A 3J1, Canada
  • Cancer Hospital Chinese Academy of Medical Sciences.
    Beijing, 100021, China
  • The Affiliated Hospital of Military Medical Sciences(The 307th Hospital of Chinese PLA)
    Beijing, 100071, China
  • Beijing Cancer Hospital
    Beijing, 100142, China
  • the First Hospital of Jilin University
    Changchun, 130021, China
  • Jilin Cancer Hospital
    Changchun, 132013, China
  • Changzhou First People's Hospital
    Changzhou, 213003, China
  • Third Affiliated Hospital of Third Military Medical University
    ChongQing, 400042, China
  • Fuzhou General Hospital, PLA Nanjing Military Area Command
    Fuzhou, 110016, China
  • Sun Yet-sen University Cancer Center
    Guangzhou, 510060, China
  • Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
    Hangzhou, 310016, China
  • Harbin Medical University Cancer Hospital
    Harbin, 150081, China
  • The 1st Affiliated Hospital of Nanchang Unversity
    Nanchang, 330006, China
  • The 81st Hospital of P.L.A.
    Nanjing City, 210002, China
  • Affiliated Hospital of Nantong University
    Nantong, 226001, China
  • Zhongshan Hospital Fudan University
    Shanghai, 200032, China
  • Fudan University Shanghai Cancer Center
    Shanghai, 200120, China
  • General Hospital of Shenyang Military Command of PLA
    Shenyang, 110016, China
  • Hebei Medical University Fourth Hospital;(Tumor Hospital of Hebei Province)
    Shijiazhuang, 050035, China
  • The First Affiliated Hospital of The Fourth Military Medical University (Xijing Hospital)
    Xi'an, 710032, China
  • The Affiliated Hospital of Xuzhou Medical College
    Xuzhou, 221000, China
  • Henan Cancer Hospital
    Zhengzhou, 450008, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, 450052, China
  • Clinical Hospital Centre Zagreb
    Zagreb, 10000, Croatia
  • Clinical Hospital Sisters of Mercy
    Zagreb, 10000, Croatia
  • Hospital Oncologia; Oncology
    Salvador, 01101, El Salvador
  • Docrates Cance Center
    Helsinki, 00180, Finland
  • Turku Uni Central Hospital; Oncology Clinics
    Turku, 20520, Finland
  • Charité-Universitätsm. Berlin; Med. Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunolo.
    Berlin, 10117, Germany
  • Universitätsklinikum Essen; Innere Klinik und Poliklinik für Tumorforschung
    Essen, 45122, Germany
  • Kliniken Essen-Mitte, Evang. Huyssens-Stiftung, Klinik für Internistische Onkologie / Haematologie
    Essen, 45136, Germany
  • Klinik Esslingen; Klinik für Allgemeine Innere Medizin, Onkologie/Haematologie
    Esslingen, 73730, Germany
  • Universitätsklinikum Hamburg-Eppendorf; Hubertus Wald Tumorzentrum
    Hamburg, 20246, Germany
  • Universitaetsklinikum Leipzig, Universitaeres Krebszentrum Leipzig (UCCL)
    Leipzig, 04103, Germany
  • Klinikum Ludwigsburg; Studiensekretariat
    Ludwigsburg, 71640, Germany
  • Universitätsmedizin der Johannes Gutenberg-Universität Mainz; II. Medizinische Klinik
    Mainz, 55131, Germany
  • Universitätsklinikum Mannheim, Tagestherapiezentrum, Interdisziplinäres Tumorzentrum
    Mannheim, 68167, Germany
  • Philipps-Universität Marburg; Klinik für Innere Med.; Schwerpunkt Hämatologie/Onkologie/Immunologie
    Marburg, 35043, Germany
  • Universitätsklinikum Ulm; Zentrum für Innere Medizin Klinik für Innere Medizin I
    Ulm, 89081, Germany
  • Medical Solution; Hematology
    Guatemala, 01-010, Guatemala
  • Semmelweis Egyetem Onkologiai Központ
    Budapest, 1083, Hungary
  • Orszagos Onkologiai Intezet; B Belgyogyaszati Osztaly
    Budapest, 1122, Hungary
  • Debreceni Egyetem, Klinikai Kozpont, Onkologiai Klinika
    Debrecen, 4032, Hungary
  • Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz;Sugarterapias Klinikai Onkologiai Intez
    Miskolc, 3526, Hungary
  • Szegedi Tudomanyegyetem, AOK, Szent-Gyorgyi Albert Klinikai Kozpont, Onkoterapias Klinika
    Szeged, 6720, Hungary
  • Seconda Universita' Degli Studi; Divsione Di Oncologia Medica
    Napoli, Campania 80131, Italy
  • Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unità Operativa Oncologia Medica
    Bologna, Emilia-Romagna 40138, Italy
  • AUSL - IRCCS Santa Maria Nuova; U.O. Day Hospital di Oncologia
    Reggio Emilia, Emilia-Romagna 42100, Italy
  • Azienda Ospedaliero-Universitaria Dipartimento Interaziendale Di Oncologia
    Udine, Friuli-Venezia Giulia 33100, Italy
  • Policlinico Universitario Agostino Gemelli
    Roma, Lazio 00168, Italy
  • Asst Papa Giovanni XXIII; Oncologia Medica
    Bergamo, Lombardia 24127, Italy
  • Irccs Ospedale San Raffaele
    Milano, Lombardia 20132, Italy
  • Irccs Istituto Europeo Di Oncologia (IEO); Oncologia Medica
    Milano, Lombardia 20141, Italy
  • Ospedali Riuniti Di Ancona; Oncology
    Ancona, Marche 60121, Italy
  • Ospedale Casa Sollievo Della Sofferenza IRCCS
    San Giovanni Rotondo, Puglia 71013, Italy
  • Azlenda Ospendaliero-Universitaria Pisana; C.O. Oncologia 2
    Pisa, Toscana 56100, Italy
  • Ospedale Misericordia E Dolce; Oncologia Medica
    Prato, Toscana 59100, Italy
  • Aichi Cancer Center Hospital; Clinical Oncology
    Aichi, 464-8681, Japan
  • Nagoya university Hospital; Gastroenterological Surgery 2
    Aichi, 466-8560, Japan
  • National Cancer Center Hospital East; Gastroenterology
    Chiba, 277-8577, Japan
  • National Hospital Organization Shikoku Cancer Center; Gastroenterology
    Ehime, 791-0280, Japan
  • Kyushu University Hospital; Surgery and Science
    Fukuoka, 812-8582, Japan
  • Gifu University Hospital; Digestive Surgery
    Gifu, 501-1194, Japan
  • Hiroshima City Hiroshima Citizens Hospital; Surgery
    Hiroshima, 730-8518, Japan
  • Kobe city Medical center General Hospital; Medical Oncology
    Hyogo, 650-0047, Japan
  • St.Marianna University School of Medicine hospital; Medical Oncology
    Kanagawa, 216-8511, Japan

Showing the first 100 of 172 sites across 32 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Tabernero J, Hoff PM, Shen L, Ohtsu A, Shah MA, Siddiqui A, Heeson S, Kiermaier A, Macharia H, Restuccia E, Kang YK. Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial. Gastric Cancer. 2023 Jan;26(1):123-131. doi: 10.1007/s10120-022-01335-4. Epub 2022 Sep 6. PubMed 36066725 ↗
  • Liu T, Qin Y, Li J, Xu R, Xu J, Yang S, Qin S, Bai Y, Wu C, Mao Y, Wu H, Ge Y, Shen L. Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial. Cancer Commun (Lond). 2019 Jun 24;39(1):38. doi: 10.1186/s40880-019-0384-6. PubMed 31234927 ↗
  • Kirschbrown WP, Wang B, Nijem I, Ohtsu A, Hoff PM, Shah MA, Shen L, Kang YK, Alsina M, Girish S, Garg A. Pharmacokinetic and exposure-response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer. Cancer Chemother Pharmacol. 2019 Sep;84(3):539-550. doi: 10.1007/s00280-019-03871-w. Epub 2019 Jun 10. PubMed 31183514 ↗
  • Tabernero J, Hoff PM, Shen L, Ohtsu A, Shah MA, Cheng K, Song C, Wu H, Eng-Wong J, Kim K, Kang YK. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2018 Oct;19(10):1372-1384. doi: 10.1016/S1470-2045(18)30481-9. Epub 2018 Sep 11. PubMed 30217672 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2013 to primary completion in Dec 2016, 41 months.

Results were first posted in Feb 2018, 1 year 2 months after primary completion.

Of 45 industry-sponsored phase 3 interventional studies under Stomach Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 55. This study's 41 months is close to that.

Counting every sponsor, half of 118 studies reached it within 52 months; a quarter within 39 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2013
First posted
Jan 24, 2013
StartActual
Jun 10, 2013
Primary completionActual
Dec 9, 2016
CompletionActual
Dec 31, 2019
Results first posted
Feb 14, 2018
Last update
Dec 30, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01774786
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jan 24, 2013
Start date
Jun 10, 2013
Primary completion
Dec 9, 2016
Completion
Dec 31, 2019
Results posted
Feb 14, 2018
Last update
Dec 30, 2020

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pertuzumab

Start the discussion